Vemurafenib (PLX4032)

For research use only. Not for use in humans.

目录号：S1267 别名： RG7204, RO5185426 中文名称：维罗非尼

Vemurafenib (PLX4032) Chemical Structure

CAS No. 918504-65-1

Vemurafenib (PLX4032, RG7204, RO5185426)是一种新型有效的B-Raf^V600E抑制剂，IC50为31 nM。Vemurafenib对B-Raf^V600E的选择性比对野生型B-Raf的选择性高10倍，在细胞实验中，选择性可高100倍以上。Vemurafenib (PLX4032, RG7204) 可诱导自噬。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 746.23	现货
10mg	RMB 567.23	现货
50mg	RMB 2213.19	现货
200mg	RMB 6308.84	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Vemurafenib (PLX4032)发表文献492篇：

Nat Biotechnol, 2021, 10.1038/s41587-021-00837-3

PubMed: 33619394 ( click the link to review the publication )

Cell Metab, 2021, S1550-4131(21)00180-7

PubMed: 33989520 ( click the link to review the publication )

Cell, 2020, 182(4):947-959.e17

PubMed: 32735851 ( click the link to review the publication )

Nat Biotechnol, 2020, 10.1038/s41587-019-0388-4

PubMed: 31959954 ( click the link to review the publication )

Cancer Cell, 2020, 37(1):85-103

PubMed: 31935375 ( click the link to review the publication )

Cancer Discov, 2019, 9(7):852-871

PubMed: 31053628 ( click the link to review the publication )

Cancer Cell, 2019, 36(1):68-83

PubMed: 31257073 ( click the link to review the publication )

Science, 2018, 361(6405)

PubMed: 30166458 ( click the link to review the publication )

Cell, 2018, 173(6):1413-1425

PubMed: 29754815 ( click the link to review the publication )

Cancer Cell, 2018, 33(2):322-336

PubMed: 29438700 ( click the link to review the publication )

Cancer Cell, 2018, 33(5):890-904.e5

PubMed: 29657129 ( click the link to review the publication )

Cancer Cell, 2018, 9;34(1):56-68.e9

PubMed: 29990501 ( click the link to review the publication )

Cell Metab, 2018, 28(6):817-832

PubMed: 30244971 ( click the link to review the publication )

Nature, 2017, 547(7664):453-457

PubMed: 28678785 ( click the link to review the publication )

Nature, 2017, 550(7674):133-136

PubMed: 28953887 ( click the link to review the publication )

Nature, 2017, 546(7658):431-435

PubMed: 28607484 ( click the link to review the publication )

Nature, 2016, 538(7626):477-482

PubMed: 27760111 ( click the link to review the publication )

Nature, 2016, 10.1038/nature19347

PubMed: 27580028 ( click the link to review the publication )

Science, 2016, 352(6282):189-96

PubMed: 27124452 ( click the link to review the publication )

Nat Biotechnol, 2016, 34(2):184-191

PubMed: 26780180 ( click the link to review the publication )

Nat Med, 2016, 22(9):1056-61

PubMed: 27500726 ( click the link to review the publication )

Nat Med, 2016, 22(6):624-31

PubMed: 27135741 ( click the link to review the publication )

Cell Stem Cell, 2016, 19(6):738-751

PubMed: 27746098 ( click the link to review the publication )

Cancer Cell, 2016, 12;30(3):485-498

PubMed: 27523909 ( click the link to review the publication )
Nature, 2015, 10.1038/nature14336

PubMed: 25807485 ( click the link to review the publication )

Cancer Discov, 2015, 5(3):264-73

PubMed: 25542447 ( click the link to review the publication )

Cancer Discov, 2015, 10.1158/2159-8290.CD-15-0913

PubMed: 26566875 ( click the link to review the publication )

Cancer Discov, 2015, 5(4):358-67

PubMed: 25673644 ( click the link to review the publication )

Nature, 2014, 3;508(7494):118-22.

PubMed: 24670642 ( click the link to review the publication )

Science, 2014, 346(6205):1255784

PubMed: 25278616 ( click the link to review the publication )

Cancer Discov, 2014, 4(1):69-79

PubMed: 24265152 ( click the link to review the publication )

Cancer Discov, 2013, 3(3):350-62

PubMed: 23288408 ( click the link to review the publication )

Nature, 2012, 26;483(7387):100-3.

PubMed: 22281684 ( click the link to review the publication )

Cell, 2012, 21;151(5):937-50.

PubMed: 23178117 ( click the link to review the publication )

Nat Med, 2012, 18(8):1239-47

PubMed: 22820643 ( click the link to review the publication )

Cancer Discov, 2012, 2(5):414-24

PubMed: 22588879 ( click the link to review the publication )

Sci Adv, 2021, 7(24)eabg0390

PubMed: 34108213 ( click the link to review the publication )

Nat Commun, 2021, 12(1):1747

PubMed: 33741929 ( click the link to review the publication )

Nucleic Acids Res, 2021, 49(8):4421-4440

PubMed: 33849069 ( click the link to review the publication )

Clin Cancer Res, 2021, clincanres.3752.2020

PubMed: 33446566 ( click the link to review the publication )

EMBO Mol Med, 2021, e13466

PubMed: 33724679 ( click the link to review the publication )

Cell Rep, 2021, 35(8):109157

PubMed: 34038718 ( click the link to review the publication )

Elife, 2021, 10e63093

PubMed: 33438577 ( click the link to review the publication )

Oncogene, 2021, 10.1038/s41388-021-01808-3

PubMed: 33947959 ( click the link to review the publication )

Genomics Inform, 2021, 19(1):e2

PubMed: 33840166 ( click the link to review the publication )

J Exp Clin Cancer Res, 2021, 40(1):22

PubMed: 33413561 ( click the link to review the publication )

J Exp Clin Cancer Res, 2021, 40(1):34

PubMed: 33468157 ( click the link to review the publication )

Cancers (Basel), 2021, 13(6)1205

PubMed: 33801977 ( click the link to review the publication )
J Clin Endocrinol Metab, 2021, dgab020

PubMed: 33524147 ( click the link to review the publication )

Front Oncol, 2021, 11:698888

PubMed: 34222023 ( click the link to review the publication )

Int J Mol Sci, 2021, 22(1)E439

PubMed: 33406789 ( click the link to review the publication )

Int J Mol Sci, 2021, 22(6)3226

PubMed: 33810045 ( click the link to review the publication )

Cancer Med, 2021, 10(8):2840-2854

PubMed: 33734579 ( click the link to review the publication )

Melanoma Res, 2021, 31(3):197-207

PubMed: 33904516 ( click the link to review the publication )

Molecules, 2021, 26(7)1867

PubMed: 33810240 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2021, 10.1007/s00280-021-04270-w

PubMed: 33860836 ( click the link to review the publication )

Biochem Biophys Res Commun, 2021, 557:213-220

PubMed: 33878610 ( click the link to review the publication )

Oncol Lett, 2021, 21(3):208

PubMed: 33574947 ( click the link to review the publication )

Oncol Lett, 2021, 21(5):394

PubMed: 33777217 ( click the link to review the publication )

J Control Release, 2021, S0168-3659(21)00085-7

PubMed: 33631225 ( click the link to review the publication )

Biomedicines, 2021, 9(1)E79

PubMed: 33467521 ( click the link to review the publication )

Cancers (Basel), 2021, 13(3)555

PubMed: 33535609 ( click the link to review the publication )

Cancers (Basel), 2021, 13(4)740

PubMed: 33578955 ( click the link to review the publication )

Sci Rep, 2021, 11(1):4390

PubMed: 33623106 ( click the link to review the publication )

Cancers (Basel), 2021, 13(3)524

PubMed: 33572972 ( click the link to review the publication )

Mol Carcinog, 2021, 60(3):201-212

PubMed: 33595872 ( click the link to review the publication )

BMC Cancer, 2021, 21(1):136

PubMed: 33549048 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2021, 10.1007/s00432-021-03545-2

PubMed: 33555379 ( click the link to review the publication )

EMBO Rep, 2021, e51436

PubMed: 33554439 ( click the link to review the publication )

Oncol Rep, 2021, 45(4)14

PubMed: 33649790 ( click the link to review the publication )

J Clin Invest, 2020, 3;130(2):853-862

PubMed: 31929186 ( click the link to review the publication )

Nat Commun, 2020, 11(1):4370

PubMed: 32873792 ( click the link to review the publication )
Nat Commun, 2020, 11;11(1):2345

PubMed: 32393797 ( click the link to review the publication )

Sci Adv, 2020, 22;6(21):eaaz8521

PubMed: 32494745 ( click the link to review the publication )

Genes Dev, 2020, 1;34(9-10):637-649

PubMed: 32241802 ( click the link to review the publication )

Cell Rep, 2020, 31(11):107764

PubMed: 32553168 ( click the link to review the publication )

Oncogene, 2020, 39(20):4132-4154

PubMed: 32238882 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-1255-y

PubMed: 32157217 ( click the link to review the publication )

Sci Signal, 2020, 28;13(629)

PubMed: 32345725 ( click the link to review the publication )

J Exp Clin Cancer Res, 2020, 39(1):38

PubMed: 32085796 ( click the link to review the publication )

Cancers (Basel), 2020, 12(6):E1500

PubMed: 32526884 ( click the link to review the publication )

Cancers (Basel), 2020, 12(10)E2951

PubMed: 33066037 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2020, 10.1111/pcmr.12905

PubMed: 32558263 ( click the link to review the publication )

Br J Cancer, 2020, 10.1038/s41416-020-0751-8

PubMed: 32063604 ( click the link to review the publication )

J Clin Endocrinol Metab, 2020, dgaa656

PubMed: 32936899 ( click the link to review the publication )

Mol Ther Oncolytics, 2020, 18:83-99

PubMed: 32637583 ( click the link to review the publication )

Cells, 2020, 13;9(5) pii: E1209

PubMed: 32414111 ( click the link to review the publication )

Cell Commun Signal, 2020, 18(1):156

PubMed: 32967672 ( click the link to review the publication )

Mol Oncol, 2020, 24

PubMed: 32330348 ( click the link to review the publication )

Aging (Albany NY), 2020, 12(1):138-155

PubMed: 31901897 ( click the link to review the publication )

Biomolecules, 2020, 10(10)E1395

PubMed: 33007949 ( click the link to review the publication )

Antioxidants (Basel), 2020, 5;9(5) pii: E384

PubMed: 32380762 ( click the link to review the publication )

Front Oncol, 2020, 3;10:442

PubMed: 32346533 ( click the link to review the publication )

Biochem Pharmacol, 2020, 171:113716

PubMed: 31751535 ( click the link to review the publication )

J Transl Med, 2020, 11;18(1):192

PubMed: 32393282 ( click the link to review the publication )

Int J Mol Sci, 2020, 18;21(8):2825

PubMed: 32325639 ( click the link to review the publication )
J Biol Chem, 2020, jbc.RA120.014615

PubMed: 32938713 ( click the link to review the publication )

J Biol Chem, 2020, 30 pii: jbc

PubMed: 32358059 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

Cancer Manag Res, 2020, 12:7231-7250

PubMed: 32982400 ( click the link to review the publication )

BMC Cancer, 2020, 20(1):129

PubMed: 32066410 ( click the link to review the publication )

PLoS One, 2020, 15(6):e0234707

PubMed: 32555626 ( click the link to review the publication )

PLoS One, 2020, 15(1):e0227187

PubMed: 31917795 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00425-8

PubMed: 32886306 ( click the link to review the publication )

Pathol Oncol Res, 2020, 10.1007/s12253-020-00834-y

PubMed: 32591993 ( click the link to review the publication )

Anticancer Drugs, 2020, 31(10):1026-1037

PubMed: 32868647 ( click the link to review the publication )

J Chemother, 2020, 32(8):437-444

PubMed: 33052075 ( click the link to review the publication )

Cells, 2020, 7;9(1). pii: E142

PubMed: 31936151 ( click the link to review the publication )

Pharmaceuticals (Basel), 2020, 14(1)E23

PubMed: 33396632 ( click the link to review the publication )

Cancer Lett, 2020, S0304-3835(20)30635-2

PubMed: 33259900 ( click the link to review the publication )

Cancers (Basel), 2020, 12(8):E2085

PubMed: 32731406 ( click the link to review the publication )

Nat Biotechnol, 2020, 10.1038/s41587-020-0600-6

PubMed: 32661438 ( click the link to review the publication )

Neoplasia, 2020, 22(9):376-389

PubMed: 32629178 ( click the link to review the publication )

Apoptosis, 2020, 25(3-4):179-191

PubMed: 32056038 ( click the link to review the publication )

Transl Oncol, 2020, 13(2):441-451

PubMed: 31911278 ( click the link to review the publication )

Data Brief, 2020, 22;30:105610

PubMed: 32382617 ( click the link to review the publication )

Commun Biol, 2020, 2;3(1):154

PubMed: 32242071 ( click the link to review the publication )

Cancers (Basel), 2020, 12(7):E1972

PubMed: 32698374 ( click the link to review the publication )

Clin Cancer Res, 2020, 10.1158

PubMed: 32034077 ( click the link to review the publication )
Cancer Cell, 2020, 38(6):872-890.e6

PubMed: 33217342 ( click the link to review the publication )

Int J Cancer, 2020, 146(7):1950-1962

PubMed: 31376303 ( click the link to review the publication )

Neoplasia, 2020, 22(10):470-483

PubMed: 32818841 ( click the link to review the publication )

Oncogenesis, 2020, 9(7):64

PubMed: 32632141 ( click the link to review the publication )

Endocrine, 2020, 10.1007/s12020-020-02417-y

PubMed: 32666385 ( click the link to review the publication )

Nat Cell Biol, 2019, 21(6):778-790

PubMed: 31160710 ( click the link to review the publication )

Nat Cell Biol, 2019, 10.1038/s41556-019-0415-1

PubMed: 31740775 ( click the link to review the publication )

Mol Cell, 2019, 76(6):872-884

PubMed: 31606273 ( click the link to review the publication )

Mol Cell, 2019, 75(4):669-682

PubMed: 31302002 ( click the link to review the publication )

Mol Cell, 2019, 74(5):1086-1102.e5

PubMed: 31101498 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5157

PubMed: 31727958 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5167

PubMed: 31727888 ( click the link to review the publication )

EMBO J, 2019, 38(15):e95874

PubMed: 31267558 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-18-2779

PubMed: 31515463 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432

PubMed: 31097454 ( click the link to review the publication )

Cancer Res, 2019, 79(9):2244-2256

PubMed: 30833419 ( click the link to review the publication )

Cell Syst, 2019, 8(2):97-108

PubMed: 30797775 ( click the link to review the publication )

Cancer Res, 2019, 79(9):2124-2135

PubMed: 30862713 ( click the link to review the publication )

Cell Rep, 2019, 27(12):3573-3586.e7

PubMed: 31216476 ( click the link to review the publication )

Cell Rep, 2019, 29(1):118-134

PubMed: 31577942 ( click the link to review the publication )

Cell Rep, 2019, 26(1):65-78

PubMed: 30605687 ( click the link to review the publication )

Cell Rep, 2019, 29(3):573-588

PubMed: 31618628 ( click the link to review the publication )

Cell Death Differ, 2019, 26(7):1267-1282

PubMed: 30254376 ( click the link to review the publication )

J Control Release, 2019, 309:158-172

PubMed: 31348978 ( click the link to review the publication )
Int J Cancer, 2019, 10.1002/ijc.32432

PubMed: 31131878 ( click the link to review the publication )

Oncogene, 2019, 38(12):2005-2019

PubMed: 30467381 ( click the link to review the publication )

Stem Cell Reports, 2019,

PubMed: 31231022 ( click the link to review the publication )

Cancer Lett, 2019, 451:79-91

PubMed: 30872078 ( click the link to review the publication )

Cancer Lett, 2019, 444:45-59

PubMed: 30583070 ( click the link to review the publication )

Cancer Lett, 2019, 451:11-22

PubMed: 30862488 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):56

PubMed: 30728057 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):48

PubMed: 30717768 ( click the link to review the publication )

Cancers (Basel), 2019, 11(10)

PubMed: 31557826 ( click the link to review the publication )

Cancers (Basel), 2019, 11(9)

PubMed: 31547367 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2019, 10.1111/pcmr.12824

PubMed: 31518489 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2019, 32(1):41-54

PubMed: 29938923 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2019, 10.1111/pcmr.12812

PubMed: 31323160 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2019, 32(2):280-291

PubMed: 30277012 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2019, 10.1111/pcmr.12841

PubMed: 31663663 ( click the link to review the publication )

Clin Epigenetics, 2019, 11(1):196

PubMed: 31842975 ( click the link to review the publication )

Cell Death Dis, 2019, 10(5):342

PubMed: 31019203 ( click the link to review the publication )

Acta Neuropathol Commun, 2019, 7(1):128

PubMed: 31391125 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(2):289-300

PubMed: 30482853 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(5):937-946

PubMed: 30926642 ( click the link to review the publication )

Endocr Relat Cancer, 2019, 26(1):197-214

PubMed: 30121624 ( click the link to review the publication )

Mol Oncol, 2019, 13(9):1836-1854

PubMed: 31115969 ( click the link to review the publication )

Mol Oncol, 2019, 13(2):480-494

PubMed: 30582770 ( click the link to review the publication )

J Cancer, 2019, 10(16):3819-3829

PubMed: 31333799 ( click the link to review the publication )
Mol Cancer Res, 2019, 10.1158/1541-7786.MCR-19-0257

PubMed: 31186280 ( click the link to review the publication )

ACS Chem Biol, 2019, 10.1021/acschembio-00191

PubMed: 31243962 ( click the link to review the publication )

Mol Pharm, 2019, 16(9):3904-3915

PubMed: 31318566 ( click the link to review the publication )

J Cell Physiol, 2019, 234(8):13220-13232

PubMed: 30569573 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(17)E4203

PubMed: 31461993 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(18)

PubMed: 31514305 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(9)

PubMed: 31027376 ( click the link to review the publication )

Sci Rep, 2019, 9(1):636

PubMed: 30679688 ( click the link to review the publication )

Sci Rep, 2019, 9(1):9943

PubMed: 31289333 ( click the link to review the publication )

Sci Rep, 2019, 9(1):14197

PubMed: 31578454 ( click the link to review the publication )

Sci Rep, 2019, 9(1):30

PubMed: 30631106 ( click the link to review the publication )

Apoptosis, 2019, 24(7-8):596-611

PubMed: 30989459 ( click the link to review the publication )

Mol Pharmacol, 2019, 96(1):36-46

PubMed: 31048548 ( click the link to review the publication )

PLoS Comput Biol, 2019, 15(6):e1007034

PubMed: 31166947 ( click the link to review the publication )

Mol Carcinog, 2019, 58(9):1680-1690

PubMed: 31211467 ( click the link to review the publication )

Mol Carcinog, 2019, 58(11):2149-2160

PubMed: 31448838 ( click the link to review the publication )

Front Pharmacol, 2019, 10:30

PubMed: 30745871 ( click the link to review the publication )

Tissue Eng Part A, 2019, 10.1089/ten.TEA.2018.0210

PubMed: 30501565 ( click the link to review the publication )

J Cell Biochem, 2019, 120(4):5315-5325

PubMed: 30320916 ( click the link to review the publication )

Invest Ophthalmol Vis Sci, 2019, 60(7):2764-2772

PubMed: 31247083 ( click the link to review the publication )

BMC Cancer, 2019, 19(1):266

PubMed: 30909892 ( click the link to review the publication )

Endocrine, 2019, 10.1007/s12020-019-02028-2

PubMed: 31377969 ( click the link to review the publication )

Endocrine, 2019, 64(2):406-413

PubMed: 30850937 ( click the link to review the publication )

Transl Oncol, 2019, 12(7):951-958

PubMed: 31096111 ( click the link to review the publication )
Oncol Rep, 2019, 41(1):570-578

PubMed: 30365150 ( click the link to review the publication )

Chembiochem, 2019, 10.1002/cbic.201900266

PubMed: 31152574 ( click the link to review the publication )

PLoS One, 2019, 14(4):e0204387

PubMed: 30995246 ( click the link to review the publication )

PLoS One, 2019, 14(6):e0217399

PubMed: 31158244 ( click the link to review the publication )

Exp Dermatol, 2019, 10.1111/exd.14010

PubMed: 31338879 ( click the link to review the publication )

J Oncol, 2019, 2019:1697913

PubMed: 31354817 ( click the link to review the publication )

Mol Cell Biochem, 2019, 10.1007/s11010-019-03554-3

PubMed: 31114933 ( click the link to review the publication )

Arch Dermatol Res, 2019, 10.1007/s00403-019-01995-w

PubMed: 31624899 ( click the link to review the publication )

Hum Cell, 2019, 10.1007/s13577-019-00270-4

PubMed: 31586300 ( click the link to review the publication )

Photodermatol Photoimmunol Photomed, 2019, 10.1111/phpp.12520

PubMed: 31618797 ( click the link to review the publication )

ACS Chem Biol, 2019, 14(7):1426-1435

PubMed: 31063355 ( click the link to review the publication )

Sci Rep, 2019, 9(1):10369

PubMed: 31316083 ( click the link to review the publication )

Cancer Res, 2019, 79(19):5074-5087

PubMed: 31416844 ( click the link to review the publication )

Exp Gerontol, 2019, 126:110691

PubMed: 31421186 ( click the link to review the publication )

Cancers (Basel), 2019, 20;12(1). pii: E28

PubMed: 31861874 ( click the link to review the publication )

Mol Ther Nucleic Acids, 2019, 18:727-738

PubMed: 31726389 ( click the link to review the publication )

Oncotarget, 2019, 10(18):1669-1687

PubMed: 30899440 ( click the link to review the publication )

Mol Cell Biol, 2019, 39(14)

PubMed: 31036568 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(8):578-588

PubMed: 31015631 ( click the link to review the publication )

Mol Cell, 2018, 69(6):923-937

PubMed: 29547721 ( click the link to review the publication )

Nat Commun, 2018, 9(1):4775

PubMed: 30429474 ( click the link to review the publication )

Nat Commun, 2018, 9(1):3440

PubMed: 30143629 ( click the link to review the publication )

Nat Commun, 2018, 9(1):579

PubMed: 29422527 ( click the link to review the publication )

Nat Commun, 2018, 9(1):28

PubMed: 29295999 ( click the link to review the publication )
Nat Commun, 2018, 9(1):5416

PubMed: 30575746 ( click the link to review the publication )

J Exp Med, 2018, 215(7):1913-1928

PubMed: 29880484 ( click the link to review the publication )

Clin Cancer Res, 2018, 10.1158/1078-0432.CCR-18-0693

PubMed: 30076136 ( click the link to review the publication )

Cancer Immunol Res, 2018, 10.1158/2326-6066

PubMed: 29382670 ( click the link to review the publication )

Cancer Res, 2018, 78(2):436-450

PubMed: 29150430 ( click the link to review the publication )

Cancer Res, 2018, 78(4):1017-1030

PubMed: 29229605 ( click the link to review the publication )

Cancer Res, 2018,

PubMed: 30026331 ( click the link to review the publication )

J Control Release, 2018, 277:48-56

PubMed: 29550398 ( click the link to review the publication )

Mol Cancer, 2018, 17(1):145

PubMed: 30290811 ( click the link to review the publication )

Oncogene, 2018, 37(7):944-952

PubMed: 29059171 ( click the link to review the publication )

Oncogene, 2018, 37(12):1576-1593

PubMed: 29326440 ( click the link to review the publication )

Oncogene, 2018, 37(24):3275-3289

PubMed: 29551771 ( click the link to review the publication )

Oncogene, 2018,

PubMed: 29483645 ( click the link to review the publication )

Adv Healthc Mater, 2018, 7(17):e1800533

PubMed: 30019396 ( click the link to review the publication )

J Exp Clin Cancer Res, 2018, 37(1):318

PubMed: 30558661 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2018, 31(2):253-266

PubMed: 28972303 ( click the link to review the publication )

Cell Death Dis, 2018, 9(2):29

PubMed: 29348439 ( click the link to review the publication )

Cell Chem Biol, 2018, 25(2):175-184

PubMed: 29249695 ( click the link to review the publication )

Oncoimmunology, 2018, 7(8):e1450127

PubMed: 30221038 ( click the link to review the publication )

Bioinformatics, 2018, 34(17):i997-i1004

PubMed: 30423075 ( click the link to review the publication )

Bioinformatics, 2018, 34(23):4079-4086

PubMed: 29931053 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(1):84-95

PubMed: 29133617 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(10):2217-2225

PubMed: 30045926 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(7):1416-1429

PubMed: 29703842 ( click the link to review the publication )
Mol Cancer Ther, 2018, 17(4):806-813

PubMed: 29167314 ( click the link to review the publication )

Endocr Relat Cancer, 2018, 25(1):99-109

PubMed: 29269566 ( click the link to review the publication )

Endocr Relat Cancer, 2018, 25(4):471-480

PubMed: 29440231 ( click the link to review the publication )

Mol Oncol, 2018, 12(6):869-882

PubMed: 29624862 ( click the link to review the publication )

Mol Oncol, 2018, 12(1):74-88

PubMed: 29112787 ( click the link to review the publication )

Mol Oncol, 2018, 12(2):224-238

PubMed: 29193645 ( click the link to review the publication )

Mol Cell Proteomics, 2018, 17(10):1892-1908

PubMed: 29970458 ( click the link to review the publication )

Cancer Biomark, 2018, 23(1):67-77

PubMed: 30010109 ( click the link to review the publication )

Neoplasia, 2018, 20(11):1121-1134

PubMed: 30265861 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(5):833-845

PubMed: 29523762 ( click the link to review the publication )

Int J Mol Sci, 2018, 19(4)

PubMed: 29570692 ( click the link to review the publication )

ACS Med Chem Lett, 2018, 9(12):1199-1204

PubMed: 30613326 ( click the link to review the publication )

Cell Signal, 2018, 42:30-43

PubMed: 28982601 ( click the link to review the publication )

Life Sci, 2018, 206:35-44

PubMed: 29782872 ( click the link to review the publication )

BMC Cancer, 2018, 18(1):675

PubMed: 29929490 ( click the link to review the publication )

BMC Cancer, 2018, 18(1):1219

PubMed: 30514258 ( click the link to review the publication )

Biochimie, 2018, 148:1-11

PubMed: 29471001 ( click the link to review the publication )

Melanoma Res, 2018, 28(5):390-397

PubMed: 30020196 ( click the link to review the publication )

Melanoma Res, 2018, 28(6):536-546

PubMed: 30124539 ( click the link to review the publication )

Melanoma Res, 2018, 28(6):521-526

PubMed: 30192303 ( click the link to review the publication )

Biol Chem, 2018, 399(7):649-659

PubMed: 29894293 ( click the link to review the publication )

PLoS One, 2018, 13(4):e0195956

PubMed: 29684045 ( click the link to review the publication )

PLoS One, 2018, 13(2):e0191696

PubMed: 29470488 ( click the link to review the publication )

Onco Targets Ther, 2018, 11:8293-8299

PubMed: 30538498 ( click the link to review the publication )
BMC Syst Biol, 2018, 12(1):33

PubMed: 29615030 ( click the link to review the publication )

Med Sci Monit, 2018, 24:3002-3010

PubMed: 29737325 ( click the link to review the publication )

Mol Biol (Mosk), 2018, 52(3):466-473

PubMed: 29989578 ( click the link to review the publication )

Sci Rep, 2018, 8(1):587

PubMed: 29330434 ( click the link to review the publication )

Cell Death Dis, 2018, 9(3):325

PubMed: 29487283 ( click the link to review the publication )

Small GTPases, 2018, 10.1080/21541248.2018.1446697

PubMed: 29634387 ( click the link to review the publication )

Oncogene, 2018, 37(31):4226-4238

PubMed: 29717260 ( click the link to review the publication )

Sci Rep, 2018, 8(1):10724

PubMed: 30013176 ( click the link to review the publication )

BMC Cancer, 2018, 18(1):675

PubMed: 29929490 ( click the link to review the publication )

Mol Biol (Mosk), 2018, 52(3):466-473

PubMed: 29989578 ( click the link to review the publication )

Cell Syst, 2018, 7(2):161-179

PubMed: 30007540 ( click the link to review the publication )

Oncotarget, 2018, 9(23):16489-16500

PubMed: 29662661 ( click the link to review the publication )

Small GTPases, 2018, 10.1080/21541248.2018.1446697

PubMed: 29634387 ( click the link to review the publication )

Oncotarget, 2018, 9(18):14567-14579

PubMed: 29581864 ( click the link to review the publication )

Biophys J, 2018, 114(6):1499-1511

PubMed: 29590606 ( click the link to review the publication )

Eur J Med Chem, 2018, 146:519-528

PubMed: 29407977 ( click the link to review the publication )

Oncotarget, 2018, 9(47):28294-28308

PubMed: 29983861 ( click the link to review the publication )

Oncogene, 2018, 37(7):944-952

PubMed: 29059171 ( click the link to review the publication )

Nat Commun, 2017, 8:15262

PubMed: 28497782 ( click the link to review the publication )

Nat Commun, 2017, 8(1):2249

PubMed: 29269732 ( click the link to review the publication )

EMBO J, 2017, 36(5):646-663

PubMed: 28093501 ( click the link to review the publication )

EMBO J, 2017, 36(5):604-616

PubMed: 28122869 ( click the link to review the publication )

Genes Dev, 2017, 31(17):1809-1820

PubMed: 28982763 ( click the link to review the publication )

Cancer Res, 2017, 77(7):1599-1610

PubMed: 28202513 ( click the link to review the publication )
Int J Cancer, 2017, 140(12):2758-2770

PubMed: 27813079 ( click the link to review the publication )

Oncogene, 2017, 36(4):446-457

PubMed: 27375018 ( click the link to review the publication )

Stem Cell Reports, 2017, 8(5):1379-1391

PubMed: 28392221 ( click the link to review the publication )

Antioxid Redox Signal, 2017, 26(15):864-877

PubMed: 27401113 ( click the link to review the publication )

Cancer Lett, 2017, 402:100-109

PubMed: 28576751 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2017, 30(5):467-476

PubMed: 28513992 ( click the link to review the publication )

Cell Death Dis, 2017, 8(2):e2594

PubMed: 28151482 ( click the link to review the publication )

Arch Toxicol, 2017, 91(8):2921-2938

PubMed: 28032146 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(5):936-947

PubMed: 28223427 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(10-:2130-2143

PubMed: 28751539 ( click the link to review the publication )

Mol Oncol, 2017, 11(12):1806-1825

PubMed: 29094484 ( click the link to review the publication )

J Cancer, 2017, 8(15):2933-2943

PubMed: 28928884 ( click the link to review the publication )

Transl Lung Cancer Res, 2017, 6(5):600-610

PubMed: 29114475 ( click the link to review the publication )

Mol Cancer Res, 2017, 15(9):1265-1274

PubMed: 28584020 ( click the link to review the publication )

Front Oncol, 2017, 7:95

PubMed: 28596940 ( click the link to review the publication )

Lab Invest, 2017, 97(2):217-227

PubMed: 28067893 ( click the link to review the publication )

Sci Rep, 2017, 7:44206

PubMed: 28287179 ( click the link to review the publication )

J Biol Chem, 2017, 292(28):11727-11739

PubMed: 28546431 ( click the link to review the publication )

Cancer Cell Int, 2017, 17:86

PubMed: 29033690 ( click the link to review the publication )

Biotechnol Bioeng, 2017, 114(12):2868-2882

PubMed: 28755500 ( click the link to review the publication )

Mol Carcinog, 2017, 56(8):1965-1976

PubMed: 28370562 ( click the link to review the publication )

Mol Cell Biol, 2017, 37(18)e00061-17

PubMed: 28674184 ( click the link to review the publication )

BMC Cancer, 2017,

PubMed: 28806950 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2017, 143(3):447-455

PubMed: 27928645 ( click the link to review the publication )
Cancer Med, 2017, 6(7):1652-1664

PubMed: 28573821 ( click the link to review the publication )

PLoS One, 2017, 12(8):e0183498

PubMed: 28829835 ( click the link to review the publication )

PLoS One, 2017, 12(5):e0177830

PubMed: 28545079 ( click the link to review the publication )

PLoS One, 2017, 12(1):e0170445

PubMed: 28118392 ( click the link to review the publication )

Int J Mol Sci, 2017, 18(10)

PubMed: 29064427 ( click the link to review the publication )

Oncotarget, 2017, 8(46):80393-80404

PubMed: 29113311 ( click the link to review the publication )

Oncoimmunology, 2017, 7(2):e1392426

PubMed: 29308322 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(29):E5930-E5939

PubMed: 28684402 ( click the link to review the publication )

JCI Insight, 2017, 2(3):e89473

PubMed: 28194436 ( click the link to review the publication )

Biochim Biophys Acta Gen Subj, 2017, 1861(11 Pt B):2980-2992

PubMed: 28408301 ( click the link to review the publication )

Oncotarget, 2017, 8(1):900-914

PubMed: 27863429 ( click the link to review the publication )

Oncotarget, 2017, 8(51):89182-89193

PubMed: 29179510 ( click the link to review the publication )

Oncotarget, 2017, 8(48):84210-84223

PubMed: 29137417 ( click the link to review the publication )

J Exp Med, 2017, 214(6):1691-1710

PubMed: 28450382 ( click the link to review the publication )

Sci Rep, 2017, 7(1):16345

PubMed: 29180761 ( click the link to review the publication )

Blood Adv, 2017, 30;1(24):2147-2160

PubMed: 29296862 ( click the link to review the publication )

Tumour Biol, 2017, 39(9):1010428317721620

PubMed: 28936920 ( click the link to review the publication )

Oncotarget, 2017, 8(49):84743-84760

PubMed: 29156680 ( click the link to review the publication )

Oncotarget, 2017, 8(7):11460-11479

PubMed: 28002790 ( click the link to review the publication )

Elife, 2017, 6. pii: e18970

PubMed: 28145866 ( click the link to review the publication )

JCI Insight, 2017, 2(3):e89473

PubMed: 28194436 ( click the link to review the publication )

Oncogene, 2017, 36(27):3842-3851

PubMed: 28263969 ( click the link to review the publication )

Cell Death Dis, 2017, 8(8):e3029

PubMed: 29048432 ( click the link to review the publication )

Hepatology, 2016, 64(2):488-500

PubMed: 27015352 ( click the link to review the publication )
J Clin Invest, 2016, 126(1):68-84

PubMed: 26595814 ( click the link to review the publication )

Genome Biol, 2016, 17:80

PubMed: 27139883 ( click the link to review the publication )

Nat Chem Biol, 2016, 12(7):531-8

PubMed: 27214401 ( click the link to review the publication )

EMBO J, 2016, 35(5):462-78

PubMed: 26668268 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(1):230-242

PubMed: 26283684 ( click the link to review the publication )

Leukemia, 2016, 30(4):937-46

PubMed: 26582644 ( click the link to review the publication )

Cancer Res, 2016, 76(9):2720-30

PubMed: 26984758 ( click the link to review the publication )

Cancer Res, 2016, 76(6):1476-84

PubMed: 26825172 ( click the link to review the publication )

EMBO Rep, 2016, 17(5):724-38

PubMed: 27013495 ( click the link to review the publication )

Cell Rep, 2016, 15(1):171-180

PubMed: 27052162 ( click the link to review the publication )

Cell Rep, 2016, 16(10):2641-2650

PubMed: 27568560 ( click the link to review the publication )

Int J Cancer, 2016, 138(9):2257-62

PubMed: 26684394 ( click the link to review the publication )

Oncogene, 2016, 35(40):5295-5303

PubMed: 27041569 ( click the link to review the publication )

J Invest Dermatol, 2016, 136(12):2475-2484

PubMed: 27498344 ( click the link to review the publication )

J Med Chem, 2016, 59(3):925-33

PubMed: 26745854 ( click the link to review the publication )

Br J Dermatol, 2016, 175(6):1221-1231

PubMed: 27145925 ( click the link to review the publication )

Cell Death Discov, 2016,

PubMed: 28028438 ( click the link to review the publication )

J Clin Endocrinol Metab, 2016, 101(3):962-71

PubMed: 26751190 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(10):2442-2454

PubMed: 27458138 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(7):1460-71

PubMed: 27196754 ( click the link to review the publication )

Endocr Relat Cancer, 2016, 23(3):135-46

PubMed: 26825960 ( click the link to review the publication )

Mol Cancer Res, 2016, 14(10):1009-1018

PubMed: 27418645 ( click the link to review the publication )

Dis Model Mech, 2016, 9(7):811-20

PubMed: 27482819 ( click the link to review the publication )

Sci Rep, 2016, 6:26803

PubMed: 27222248 ( click the link to review the publication )
J Biol Chem, 2016, 291(9):4323-33

PubMed: 26740622 ( click the link to review the publication )

Am J Cancer Res, 2016, 6(5):1040-52

PubMed: 27293997 ( click the link to review the publication )

Mol Cell Endocrinol, 2016, 431:123-32

PubMed: 27173027 ( click the link to review the publication )

Oncotarget, 2016, 8(35):58021-58036

PubMed: 28938534 ( click the link to review the publication )

EMBO Mol Med, 2016, 8(10):1143-1161

PubMed: 27596438 ( click the link to review the publication )

Oncotarget, 2016, 7(21):30453-60

PubMed: 27028853 ( click the link to review the publication )

Oncotarget, 2016, 7(34):55128-55140

PubMed: 27391157 ( click the link to review the publication )

Oncotarget, 2016, 7(44):71211-71222

PubMed: 27655717 ( click the link to review the publication )

Oncotarget, 2016, 7(15):19948-59

PubMed: 26942566 ( click the link to review the publication )

Oncogene, 2016, 35(17):2166-77

PubMed: 26279295 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(6):1163-76

PubMed: 27048951 ( click the link to review the publication )

Oncotarget, 2016, 7(38):60858-60871

PubMed: 27563819 ( click the link to review the publication )

Oncotarget, 2016, 7(15):19948-59

PubMed: 26942566 ( click the link to review the publication )

Oncotarget, 2016, 7(4):3947-65

PubMed: 26678033 ( click the link to review the publication )

Oncotarget, 2016, 7(15):19997-20015

PubMed: 26918352 ( click the link to review the publication )

Oncotarget, 2016, 7(15):19575-88

PubMed: 26988909 ( click the link to review the publication )

Oncotarget, 2016, 7(43):70779-70793

PubMed: 27683122 ( click the link to review the publication )

Oncotarget, 2016, 7(14):17665-80

PubMed: 26771234 ( click the link to review the publication )

Sci Rep, 2016, 6:23713

PubMed: 27025703 ( click the link to review the publication )

Oncotarget, 2016, 7(21):30907-23

PubMed: 27127178 ( click the link to review the publication )

Sci Rep, 2016, 6:27454

PubMed: 27273450 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2016, 113(34):E5005-13

PubMed: 27503895 ( click the link to review the publication )

Oncotarget, 2016, 7(46):75839-75853

PubMed: 27713119 ( click the link to review the publication )

Nat Cell Biol, 2015, 17(3):322-332

PubMed: 25720964 ( click the link to review the publication )
Mol Cell, 2015, 57(3):521-36

PubMed: 25658204 ( click the link to review the publication )

Nat Struct Mol Biol, 2015, 22(1):37-43

PubMed: 25437913 ( click the link to review the publication )

Nat Commun, 2015, 6:7103

PubMed: 25971842 ( click the link to review the publication )

J Natl Cancer Inst, 2015, 108(6):djv406

PubMed: 26719346 ( click the link to review the publication )

Cancer Res, 2015, 75(21):4573-81

PubMed: 26363009 ( click the link to review the publication )

Cell Rep, 2015, 10.1016/j.celrep.2015.04.049

PubMed: 26027934 ( click the link to review the publication )

Mol Cancer, 2015, 14:128

PubMed: 26134498 ( click the link to review the publication )

Elife, 2015, 4

PubMed: 26284497 ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2015.97

PubMed: 25867065 ( click the link to review the publication )

Cancer Lett, 2015, 10.1016/j.canlet.2015.02.041

PubMed: 25725450 ( click the link to review the publication )

J Invest Dermatol, 2015, 135(7):1863-1872

PubMed: 25789707 ( click the link to review the publication )

J Med Chem, 2015, 58(4):1818-31

PubMed: 25611072 ( click the link to review the publication )

Biochem Pharmacol, 2015, 93(3):290-304

PubMed: 25529535 ( click the link to review the publication )

Biochem Pharmacol, 2015, 93(3):290-304

PubMed: ( click the link to review the publication )

J Transl Med, 2015, 13:191

PubMed: 26070816 ( click the link to review the publication )

J Transl Med, 2015, 13(1):37

PubMed: 25627962 ( click the link to review the publication )

J Biol Chem, 2015, 290(40):24267-77

PubMed: 26269601 ( click the link to review the publication )

J Immunother, 2015, 38(1):12-23

PubMed: 25415284 ( click the link to review the publication )

Int J Oncol, 2015, 47(1):81-90

PubMed: 25997619 ( click the link to review the publication )

Proteomics, 2015, 15(2-3):327-39

PubMed: 25339196 ( click the link to review the publication )

Cell Signal, 2015, 27(10):1939-48

PubMed: 26163823 ( click the link to review the publication )

PLoS One, 2015, 10(2):e0118210

PubMed: 25706985 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0123410

PubMed: 25844720 ( click the link to review the publication )

Leuk Res, 2015, 10.1016/j.leukres.2015.08.017

PubMed: 26350141 ( click the link to review the publication )
Cancer Res, 2015, 75(1):216-29

PubMed: 25381152 ( click the link to review the publication )

EMBO Mol Med, 2015, 7(9):1104-18

PubMed: 26105199 ( click the link to review the publication )

Oncotarget, 2015, 6(19):16902-11

PubMed: 26160848 ( click the link to review the publication )

Biochem Pharmacol, 2015, 93(3):290-304

PubMed: 25529535 ( click the link to review the publication )

Oncotarget, 2015, 6(36):39028-35

PubMed: 26472021 ( click the link to review the publication )

Oncotarget, 2015, 6(19):16902-11

PubMed: 26160848 ( click the link to review the publication )

Oncotarget, 2015, 6(31):31792-804

PubMed: 26397139 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26172302 ( click the link to review the publication )

PLoS One, 2015, 10(2):e0118210

PubMed: 25706985 ( click the link to review the publication )

J Invest Dermatol, 2015, 135(7):1863-1872

PubMed: 25789707 ( click the link to review the publication )

Oncotarget, 2015, 6(18):16488-506

PubMed: 26029997 ( click the link to review the publication )

Oncotarget, 2015, 6(28):24823-41

PubMed: 26208478 ( click the link to review the publication )

Oncotarget, 2015, 6(38):40535-56

PubMed: 26497853 ( click the link to review the publication )

Blood, 2014, 123(20):3152-5

PubMed: 24652991 ( click the link to review the publication )

J Clin Invest, 2014, 124(11):5074-84

PubMed: 25329694 ( click the link to review the publication )

Nat Commun, 2014, 5:3901

PubMed: 24849047 ( click the link to review the publication )

Autophagy, 2014, 10(6):1120-36

PubMed: 24879157 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(13):3446-57

PubMed: 24812408 ( click the link to review the publication )

Cancer Res, 2014, 74(15):4122-32

PubMed: 25035390 ( click the link to review the publication )

Cancer Res, 2014, 74(17):4845-52

PubMed: 25056119 ( click the link to review the publication )

Cancer Res, 2014, 74(4):1067-78

PubMed: 24398473 ( click the link to review the publication )

Cancer Res, 2014, 74(15):4122-32

PubMed: 25035390 ( click the link to review the publication )

Cell Death Differ, 2014, 21(12):1936-49

PubMed: 25215949 ( click the link to review the publication )

Mol Cancer, 2014, 13:194

PubMed: 25142146 ( click the link to review the publication )
Eur J Cancer, 2014, 50(7):1310-20

PubMed: 24559688 ( click the link to review the publication )

Oncogene, 2014, 10.1038/onc.2014.21

PubMed: 24608435 ( click the link to review the publication )

Cancer Lett, 2014, 355(1):130-40

PubMed: 25218351 ( click the link to review the publication )

J Invest Dermatol, 2014, 134(6):1686-92

PubMed: 24434746 ( click the link to review the publication )

J Invest Dermatol, 2014, 134(2):430-40

PubMed: 23955071 ( click the link to review the publication )

Br J Dermatol, 2014, 10.1111/bjd.13300

PubMed: 25066094 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1278

PubMed: 24901049 ( click the link to review the publication )

Development, 2014, 141(13):2611-20

PubMed: 24924195 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(7):1894-906

PubMed: 24825855 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(2):353-63

PubMed: 24398428 ( click the link to review the publication )

Mol Cancer Ther, 2014, 10.1158/1535-7163.MCT-14-0452

PubMed: 25349308 ( click the link to review the publication )

J Transl Med, 2014, 12(1):247

PubMed: 25182332 ( click the link to review the publication )

Pharm Res, 2014, 31(12):3487-502

PubMed: 24919932 ( click the link to review the publication )

Cell Cycle, 2014, 13(24):3808-17

PubMed: 25426675 ( click the link to review the publication )

Arch Biochem Biophys, 2014, 563:125-35

PubMed: 25026375 ( click the link to review the publication )

J Pharm Pharm Sci, 2014, 17(1):154-68

PubMed: 24735766 ( click the link to review the publication )

Biomed Res Int, 2014, 2014:568693

PubMed: 25309914 ( click the link to review the publication )

Arch Dermatol Res, 2014, 306(10):873-84

PubMed: 25073704 ( click the link to review the publication )

J Surg Res, 2014, 190(1):111-8

PubMed: 24655664 ( click the link to review the publication )

Anticancer Res, 2014, 34(9):4857-68

PubMed: 25202067 ( click the link to review the publication )

Target Oncol, 2014, 10.1007/s11523-014-0318-9

PubMed: 24824730 ( click the link to review the publication )

Oncotarget, 2014, 5(9):2513-28

PubMed: 24810336 ( click the link to review the publication )

Oncotarget, 2014, 5(20):10127-39

PubMed: 25333256 ( click the link to review the publication )

Oncotarget, 2014, 5(19):9444-59

PubMed: 25275294 ( click the link to review the publication )
Am J Clin Exp Immunol, 2014, 3(1):43-56

PubMed: 24660121 ( click the link to review the publication )

Rostock University, 2014, Lange F

PubMed: ( click the link to review the publication )

Oncotarget, 2014, 5(24):12607-20

PubMed: 25557167 ( click the link to review the publication )

Oncotarget, 2014, 5(20):10127-39

PubMed: 25333256 ( click the link to review the publication )

Oncotarget, 2014,

PubMed: 25277205 ( click the link to review the publication )

Oncotarget, 2014, 5(21):10732-44

PubMed: 25313141 ( click the link to review the publication )

Nat Chem Biol, 2013, 9(5):307-12

PubMed: 23502424 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(9):2584-91

PubMed: 23515407 ( click the link to review the publication )

Blood Cancer J, 2013, 3:e163

PubMed: 24270325 ( click the link to review the publication )

Thyroid, 2013, 24(3):453-62

PubMed: 23998804 ( click the link to review the publication )

J Invest Dermatol, 2013, 133(8):2041-9

PubMed: 23344460 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2013, 27(1):124-33

PubMed: 24112705 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2013, 26(6):845-51

PubMed: 23890088 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e914

PubMed: 24201813 ( click the link to review the publication )

J Clin Endocrinol Metab, 2013, 98(6):2502-12

PubMed: 23559083 ( click the link to review the publication )

J Clin Endocrinol Metab, 2013, 98(8):E1422-7

PubMed: 23766517 ( click the link to review the publication )

Mol Cancer Ther, 2013, 12(7):1171-9

PubMed: 23615632 ( click the link to review the publication )

Oncogenesis, 2013, 2:e44

PubMed: 23588493 ( click the link to review the publication )

J Transl Med, 2013, 11:180

PubMed: 23890105 ( click the link to review the publication )

J Endocrinol Invest, 2013, 36(11):1099-104

PubMed: 24084189 ( click the link to review the publication )

Cancer Med, 2013, 2(1):76-85

PubMed: 24133630 ( click the link to review the publication )

J Biomol Screen, 2013, 19(4):526-37

PubMed: 24361645 ( click the link to review the publication )

Am J Med Sci, 2013, 346(6):494-8

PubMed: 24051957 ( click the link to review the publication )

Vet J, 2013, 198(3):577-82

PubMed: 24035468 ( click the link to review the publication )
Elife, 2013, 2:e00969

PubMed: 24192036 ( click the link to review the publication )

Sci Transl Med, 2012, 4(136):136ra70

PubMed: 22649091 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2012, 109(31):E2127-33

PubMed: 22773810 ( click the link to review the publication )

J Invest Dermatol, 2012, 133(5):1269-77

PubMed: 23190890 ( click the link to review the publication )

Oncoimmunology, 2012, 1(9):1476-1483

PubMed: 23264894 ( click the link to review the publication )

ACS Chem Biol, 2012, 7(8):1429-35

PubMed: 22625864 ( click the link to review the publication )

J Transl Med, 2012, 10:15

PubMed: 22277029 ( click the link to review the publication )

J Biol Chem, 2012, 287(35):29887-98

PubMed: 22767597 ( click the link to review the publication )

PLoS One, 2012, 7(5):e36762

PubMed: 22675422 ( click the link to review the publication )

PLoS One, 2012, 7(12):e52760

PubMed: 23285177 ( click the link to review the publication )

PLoS One, 2012, 7(10):e47696

PubMed: 23110092 ( click the link to review the publication )

J Invest Dermatol, 2011, 131(10):2087-95

PubMed: 21753785 ( click the link to review the publication )

产品安全说明书

Raf抑制剂选择性比较

生物活性

产品描述

特性

PLX4032是新型有效的B-RAF^V600E 肿瘤蛋白抑制剂。

靶点

SRMS ^[1] (Cell-free assay)	ACK1 ^[1] (Cell-free assay)	B-Raf (V600E) ^[1] (Cell-free assay)	C-Raf ^[1] (Cell-free assay)	MAP4K5 (KHS1) ^[1] (Cell-free assay)	点击更多
18 nM	19 nM	31 nM	48 nM	51 nM	点击更多

体外研究

PLX4032抑制B-RAF^V600E, C-RAF, 和野生型B-RAF, IC50分别为31 nM, 48 nM, 和100 nM。PLX4032 也抑制一些非-RAF激酶,包括ACK1, KHS1,和SRMS, IC50 为18 nM 到51 nM。^[1] PLX4032作用于黑色素瘤细胞系，抑制效果依赖于B-RAF突变状态，因为PLX4032有效抑制含B-RAF^V600突变的细胞, 包括V600E, V600D, V600K, 和V600R, 但是对野生型或其他突变没有作用效果。PLX4032作用于MALME-3M, Colo829, Colo38, A375, SK-MEL28, 和A2058细胞时，IC50为20 nM 到 1 μM。0.1 μM 到30 μM PLX4032 也抑制MEK1/2 和ERK1/2磷酸化作用。^[2] PLX4032高效作用于黑色素瘤的治疗，因为PLX4032有效抑制B-RAF^V600E。PLX4032作用于结肠癌细胞，抑制B-RAF ^V600E导致 EGFR激活的快速回应，可用于补偿PLX4032抑制的细胞增殖。^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
SKMEL19	NYrJZlA2TnWwY4Tpc44hSXO\|YYm=	M2n1dlYh\|ryP	NWXYSWNQPDhiaB?=	MYnEUXNQ	NYS2dnB7XHKrZ3fldpMhTVJic4Ty[ZN{	NGn4[3Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{O2NlI1OCd-MkOzOlIzPDB:L3G+
VMM12	NWGyR4t{TnWwY4Tpc44hSXO\|YYm=	NUTVbopVOyEQvF2=	NHT3Soc1QCCq	NX;6b41uTE2VTx?=	MYXJcoNz\WG\|ZYOgZ49tdGGpZX6gd5lvfGinc3nzJIFv\CCmZXPy[YF{\XNiSVytPUBmgHC{ZYPzbY9v	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTl6OUWwOkc,OjV7OEm1NFY9N2F-
C4	M{fvVGZ2dmO2aX;uJGF{e2G7	M1TUPFMh\|ryP	Mn\YOFghcA>?	NVr0dIFQTE2VTx?=	MknwTY5kemWjc3XzJINwdGyjZ3XuJJN6dnSqZYPpd{BidmRiZHXjdoVie2W\|IFnMMVgh\XiycnXzd4lwdg>?	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTl6OUWwOkc,OjV7OEm1NFY9N2F-
Calu-6	MlTkSpVv[3Srb36gRZN{[Xl?	NEe3VIwy6oDLzszN	MkPFNUBp	MWTEUXNQ	MlTLRYN1cX[jdHXzJG1GUy:HUlugbY4h[2WubIOge4l1cCC5aXzkMZR6eGViQmLBSi=>	M2\YV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMUe5O\|A2Lz5{MEG3PVcxPTxxYU6=
PC	M4TnTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NX\pOlBZQTZiaB?=		NFPhXHlGSzVyPjCxNFAxKG6P	M1yyN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OEiwO\|kzLz5zOUi4NFc6OjxxYU6=
TPC-1 (RET/PTC1)	M4q2W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NHjR[ow6PiCq		M1XqW2VEPTEkibWxNFAxKG6P	M1jQc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OEiwO\|kzLz5zOUi4NFc6OjxxYU6=
CAL62 (KRAS G12R) > 1000 > 1000	NIDMUWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MlLZPVYhcA>?		MUXFR\|UxRiBzMECwJI5O	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTh6MEe5Nkc,OTl6OEC3PVI9N2F-
HTH7 (NRAS Q61R)	MonYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NWHYenAzQTZiaB?=		NHrKcnlGSzVy4polJFExODBibl2=	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTh6MEe5Nkc,OTl6OEC3PVI9N2F-
C643 (HRAS G13R)≥ 500	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NUT3cJl2QTZiaB?=		NE[5cGVGSzVyIPMJqUA2ODBibl2=	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTh6MEe5Nkc,OTl6OEC3PVI9N2F-
BCPAP (BRAF WT/V600E)	Moi2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NG\Xb\|Y6PiCq		NIT6dppGSzVyPUe4JI5O	NF[wUVA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUi4NFc6Oid-MUm4PFA4QTJ:L3G+
BHT101 (BRAF WT/V600E)	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M1zPdlk3KGh?		NYq5fIlOTUN3ME25O{BvVQ>?	Mn;LQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl6OEC3PVIoRjF7OEiwO\|kzRC:jPh?=
SW1736 (BRAF WT/V600E)	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MXi5OkBp		NF7JdZZGSzVyPUK5JI5O	M2n6[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OEiwO\|kzLz5zOUi4NFc6OjxxYU6=
8505C (BRAF V600E/V600E)	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MVO5OkBp		NXHDXVZ2TUN3ME21O{BvVQ>?	NFKzfGY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUi4NFc6Oid-MUm4PFA4QTJ:L3G+
ARO	MV3GeY5kfGmxbjDBd5NigQ>?	MYKxNEDPxE1?	M3HRelczKGh?	MUTEUXNQ	NH;DW4hKdmS3Y3XzJJRp\SC{ZXX4dJJme3Orb36gc4YhfGinIF7JV{BxfW2y	M3;HTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NEW4NFU{Lz5zOES1PFA2OzxxYU6=
A375	NV[5ZlZ{SXCxcITvd4l{KEG\|c3H5	NU\0ZYRTOTBizszN		MnnnSG1UVw>?	NWXrcYFOWHKxbX;0[ZMh[XCxcITveIlkKGSnYYTo	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDR3OEC1N{c,OTh2NUiwOVM9N2F-
TPCI	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmrNNVAxKM7:TR?=	MmDOPVYhcA>?	NHXRUWxFVVOR	MoPHTWM2OD1zMD63O{DPxE1?	MnjvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh2NUiwOVMoRjF6NEW4NFU{RC:jPh?=
ARO	M3r6bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV:xNFAh\|ryP	NF;4Rog6PiCq	M1PhUGROW09?	M3PORWlEPTB;MkC1JI5O	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDR3OEC1N{c,OTh2NUiwOVM9N2F-
NPA	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH:1NpkyODBizszN	M17lO\|k3KGh?	NYHBdJNNTE2VTx?=	Mn;TTWM2OD1{NjDuUS=>	M3fueFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NEW4NFU{Lz5zOES1PFA2OzxxYU6=
A375	NW\oRlVIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHKzUlIyODBizszN	MlrPPVYhcA>?	M3fVW2ROW09?	NFrxTJFKSzVyPUS3JI5O	NFHjcFY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOES1PFA2Oyd-MUi0OVgxPTN:L3G+
UKF-NB-3 (ABCB1)	NUPj[lk5TnWwY4Tpc44hSXO\|YYm=	Mm[yNU4zPSEEtV2=	NXSyU4lYOiCq	NIjMR2JFVVOR	Ml;mSY5p[W6lZYOgZYNkfW23bHH0bY9vKG:oIITo[UBndHWxcnXzZ4VvfCCDQlPCNUB{fWK\|dILheIUhemixZHHtbY5mKDF{Mx?=	M{XwSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{O1O\|Y3Lz5{NEezOVc3PjxxYU6=
UKF-NB-3	MmrsSpVv[3Srb36gRZN{[Xl?	NYT3cmRCOS5{NTFCuW0>	Mnn1NkBp	NXPsO\|RbTE2VTx?=	M2nIZXNq\26rZnnjZY51dHliYX\m[YN1eyCxbjDhZ4N2dXWuYYTpc44hd2ZidHjlJIZtfW:{ZYPj[Y51KEGEQ1KxJJN2[nO2cnH0[UBzcG:mYX3pcoUhOTJ\|	NH;wemY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEezOVc3Pid-MkS3N\|U4PjZ:L3G+
A375 (BRAFV600E)	Moq0SpVv[3Srb36gRZN{[Xl?		Mn;BPEBp	NEjkSWdFVVOR	Mk\MTY5kemWjc3XzJIlvfHKjY3XscJVt[XJiUl;TJIFv\CCQTzDs[ZZmdHN?	NXyxZms6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzOlM3PDRpPkK1N\|Y{PjR2PD;hQi=>
A375P	MVjBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?				M13RfGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUO3OXAh[2WubIOsJGlEPTBiPTCwMlI2PCEQvF2u	NV3TOFNyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK0OlAxOzBpPkKyOFYxODNyPD;hQi=>
A375	MYHBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?				NYPLNFdJSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBN\|c2KGOnbHzzJIV5eHKnc4PpcochSi2UYX[gWlYxOEVibYX0ZY51KGGwZDD3bYxlKHS7cHWgVoF{NCCLQ{WwJF0hOC5\|MTFOwG0v	MoTuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ6MEi5NVEoRjJ{OEC4PVEyRC:jPh?=
A375P	M{C3NmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		M2jxW\|Q5KGi{cx?=		MUnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEF\|N{XQJINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSByLkK1JO69VS5?	M2ezOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUK4OFExLz5{NEGyPFQyODxxYU6=
A375	M3zUTmN6fG:2b4jpZ4l1gSCjc4PhfS=>		MYm3NkBpenN?		NV7JdmRpS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTN5NTDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOC5zODFOwG0v	NGHl[pI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEKxOVgyQCd-MkSyNVU5OTh:L3G+
SK-MEL-28	MV\DfZRwfG:6aXPpeJkh[XO\|YYm=				MnXQR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV2suVUWOLUK4JINmdGy\|IHX4dJJme3OrbnegRk1z[WZiVk[wNGUhdXW2YX70MEBKSzVyIE2gNE4yKM7:TT6=	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR5MUS2Okc,OjR2N{G0OlY9N2F-
M229	M165OGN6fG:2b4jpZ4l1gSCjc4PhfS=>				MlvtR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUVIzQSClZXzsd{BmgHC{ZYPzbY5oKEJvcnHmJHY3ODCHIH31eIFvfCxiSVO1NEA:KDBwMTFOwG0v	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR5MUS2Okc,OjR2N{G0OlY9N2F-
M263	M2\KU2N6fG:2b4jpZ4l1gSCjc4PhfS=>				NG\sdnFEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOOjZ\|IHPlcIx{KGW6cILld5NqdmdiQj3yZYYhXjZyMFWgcZV1[W62LDDJR\|UxKD1iMD6xJO69VS5?	NYXCSFRjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0O\|E1PjZpPkK0OFcyPDZ4PD;hQi=>
M321	NXKwU4NDS3m2b4TvfIlkcXS7IHHzd4F6				NYLKNoVYS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVTN{MTDj[YxteyCneIDy[ZN{cW6pIFKtdoFnKFZ4MEDFJI12fGGwdDygTWM2OCB;IECuNUDPxE1w	M13ZdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEexOFY3Lz5{NES3NVQ3PjxxYU6=
M238	M{\0U2N6fG:2b4jpZ4l1gSCjc4PhfS=>				MXvDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNNlM5KGOnbHzzJIV5eHKnc4PpcochSi2{YX[gWlYxOEVibYX0ZY51NCCLQ{WwJF0hOC5zIN88UU4>	NI\XNmM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NES3NVQ3Pid-MkS0O\|E1PjZ:L3G+
M262	MWDDfZRwfG:6aXPpeJkh[XO\|YYm=				M1TRPGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG0zPjJiY3XscJMh\XiycnXzd4lv\yCELYLh[kBXPjByRTDteZRidnRuIFnDOVAhRSByLkGg{txONg>?	NF3RdWw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NES3NVQ3Pid-MkS0O\|E1PjZ:L3G+
M249	M4nYVWN6fG:2b4jpZ4l1gSCjc4PhfS=>				MYHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNNlQ6KGOnbHzzJIV5eHKnc4PpcochSi2{YX[gWlYxOEVibYX0ZY51NCCLQ{WwJF0hOC5zIN88UU4>	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR5MUS2Okc,OjR2N{G0OlY9N2F-
M14	NV3xcVRPS3m2b4TvfIlkcXS7IHHzd4F6				NVWxN4ZJS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVTF2IHPlcIx{KGW6cILld5NqdmdiTmLBV{BIOTKFIH31eIFvfCxiSVO1NEA:KDBwMUWg{txONg>?	NUDXblNGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0O\|E1PjZpPkK0OFcyPDZ4PD;hQi=>
SK-MEL-28	M321bmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MVu2PEBpenN?		MmKzRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCVSz3NSWwuOjhiY3XscJMhcGG{Yn;ybY5oKEKUQV[gWlYxOEVibYX0ZY51KGGodHXyJFY5KGi{czDifUBOXFNiYYPzZZktKEmFNUCgQUAxNjR6IN88UU4>	NWG1ZoZGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1PFgxPzNpPkK0OVg5ODd\|PD;hQi=>
insect cell	M{jpNWZ2dmO2aX;uJIF{e2G7		NGHyS5I3OCCvaX7z		MUDJcohq[mm2aX;uJI9nKG[3bHygcIVv\3SqIHj1cYFvKEJvUnHmJHY3ODCHIH31eIFvfCCneIDy[ZN{\WRiaX6gZoFkfWyxdnnyeZMhcW6oZXP0[YQhcW6\|ZXP0JINmdGy\|IHHzd4V{e2WmIHHzJHto[W2vYT2zN3BecW6lb4Lwc5JifGmxbjDpcpRwKE2HSzDh[pRmeiB4MDDtbY5{KGK7IIPjbY51cWyuYYTpc44h[2:3boTpcoctKEmFNUCgQUAxNjB\|MTFOwG0v	NULNUYdGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFA{OTVpPkK0PVAxOzF3PD;hQi=>
MALME-3M	NHfxNlFHfW6ldHnvckBie3OjeR?=		NYLIboltOSCqch?=		M2LwT2lvcGmkaYTpc44hd2ZiQj3SZYYhXjZyMFWgcZV1[W62LX3l[IlifGWmIFXyb{BxcG:\|cHjvdplt[XSrb36gbY4hcHWvYX6gUWFNVUVvM12gZ4VtdHNiYX\0[ZIhOSCqcjDifUBndHWxcnXzZ4Vv[2ViYX7hcJl{cXNuIFnDOVAhRSByLkC2NUDPxE1w	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlyMEOxOUc,OjR7MECzNVU9N2F-
A375	M3PieGZ2dmO2aX;uJIF{e2G7		MUGxJIhz		MkXxTY5pcWKrdHnvckBw\iCELWLh[kBXPjByRTDteZRidnRvbXXkbYF1\WRiRYLrJJBpd3OyaH;yfYxifGmxbjDpckBpfW2jbjDBN\|c2KGOnbHzzJIFnfGW{IEGgbJIh[nliZnz1c5Jme2OnbnPlJIFv[Wy7c3nzMEBKSzVyIE2gNE4yQSEQvF2u	NFH6eYo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFMyPSd-MkS5NFA{OTV:L3G+
COLO205	MmLsR5l1d3SxeHnjbZR6KGG\|c3H5		NUjYN45{PCCmYYnz		MVXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDDU2xQOjB3IHPlcIx{KGGodHXyJFQh\GG7czDifUBE\WyuVHn0[ZIuT2yxIHHzd4F6NCCHQ{WwJF0hOC5{NDFOwG0v	MoT2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MECzNVUoRjJ2OUCwN\|E2RC:jPh?=
WM266.4	NU\Pb2V[SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M1XXN\|Q5KGi{cx?=		MVrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFePMk[2MlQh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuNFYh\|ryPLh?=	MlP4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{NkewNFYoRjJ3Mk[3NFA3RC:jPh?=
A375	NIPRZphCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NH\4UXc1QCCqcoO=		NV\nTmM5SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBN\|c2KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCwMlE6KM7:TT6=	NH\ie409[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK2O\|AxPid-MkWyOlcxODZ:L3G+
WM1361	NUPxUJlLSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NIHrV3U1QCCqcoO=		MWHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFePMUO2NUBk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMT64O{DPxE1w	M2PCPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mk[3NFA3Lz5{NUK2O\|AxPjxxYU6=
A375	NG\mZpVHfW6ldHnvckBie3OjeR?=				NWXRUmdQUW6qaXLpeIlwdiCxZjDCMZJi\iCYNkCwSUBufXSjboSgbY4hcHWvYX6gRVM4PSClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gSXJMOS9{IIDoc5NxcG:{eXzheIlwdiCrbnP1ZoF1\WRiZn;yJFkxKG2rboOgZpkhX2W\|dHXyckBjdG:2dHnu[{Bu\XSqb3SsJGlEPTBiPTCwMlA{OzFizszNMi=>	M2LxeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NE[yNlY4Lz5{NUS2NlI3PzxxYU6=
A375	NG[0R\|ZCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		M1\rbFczKGi{cx?=		NVTBTHhiSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBN\|c2KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDDR2s5KGG\|c3H5MEBKSzVyIE2gN{4{OTVizszNMi=>	NGLsO\|g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUS2NlI3Pyd-MkW0OlIzPjd:L3G+
SK-MEL-2	NV;MOZp[TnWwY4Tpc44h[XO\|YYm=				MlG5TY5pcWKrdHnvckBw\iC5aXzkJJR6eGViQj3yZYYhcW5iaIXtZY4hW0tvTVXMMVIh[2WubIOgZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKGmwIFXST\|EwOiCyaH;zdIhwenmuYYTpc44hcW6ldXLheIVlKG[xcjC5NEBucW6\|IHL5JHdme3Sncn6gZoxwfHSrbnegcYV1cG:m	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR4MkK2O{c,OjV2NkKyOlc9N2F-
A375	M2DZOWZ2dmO2aX;uJIF{e2G7		NInrdIQ4OiCqcoO=		NE\5PFhKdmirYnn0bY9vKG:oIFLSRWYhXjZyMFWgcZV1[W62IHnuJIh2dWGwIFGzO\|Uh[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjDFVmsheGixc4Doc5J6dGG2aX;uJI1m[XO3cnXkJIFnfGW{IEeyJIhzeyCkeTDFUGlUSSCjc4PhfUwhUUN3MDC9JFAvOTVizszNMi=>	NH7FTVI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUm2OVgxPCd-MkW5OlU5ODR:L3G+
A375	MmHwRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		M1K2VFczKGi{cx?=		M4O1b2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUO3OUBk\WyuczDh[pRmeiB5MjDodpMh[nlicnXzZZp2emmwIHHzd4F6NCCLQ{WwJF0hOC5zNzFOwG0v	Ml2zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7NkW4NFQoRjJ3OU[1PFA1RC:jPh?=
A375	Mk\rSpVv[3Srb36gZZN{[Xl?		NF7mdFcyPSCvaX7z		NIDsb5NEd22yZYTpeIl3\SCkaX7kbY5oKGGoZnnubZR6KHSxIFLSRWYhcW5iaIXtZY4hSTN5NTDj[YxteyCjZoTldkAyPSCvaX7zJIlvKHC{ZYPlcoNmKG:oIFHUVEBidmGub3f1[UwhUUN3MDC9JFAvOjZizszNMi=>	NXHxXZExRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5OlU5ODRpPkK1PVY2QDB2PD;hQi=>
A375	MXnGeY5kfGmxbjDhd5NigQ>?		MkfhNVUhdWmwcx?=		NYK4SVc5S2:vcHX0bZRqfmViYnnu[Ilv\yCjZn\pcol1gSC2bzDBVmFHKGmwIHj1cYFvKEF\|N{WgZ4VtdHNiYX\0[ZIhOTVibXnud{BqdiCycnXz[Y5k\SCxZjDBWHAh[W6jbH;neYUtKEmFNUCgQUAxNjl3IN88UU4>	NVW3Zph7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5OlU5ODRpPkK1PVY2QDB2PD;hQi=>
HCT116	M3rzUmZ2dmO2aX;uJIF{e2G7				MY\Jcohq[mm2aX;uJI9nKEuUQWOgS\|E{TCCvdYThcpQhcW5iaIXtZY4hUEOWMUG2JINmdGy\|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiRWLLJJBpd3OyaH;yfYxifGmxbjDifUBGVEmVQTygTWM2OCB;IEG2MlYh\|ryPLh?=	NEW0dYI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUm2OVgxPCd-MkW5OlU5ODR:L3G+
HCT116	NU\hSZZlTnWwY4Tpc44h[XO\|YYm=	MlnJNE4{PCC2bzCyNFAxOCCwTR?=			NEWxOGpR[XKjZH;4bYNidCCjY4TpeoF1cW:wIH;mJHJCWy:UQV[vUWVMKHOrZ37hcIlv\yCyYYToe4F6KGmwIHj1cYFvKEiFVEGxOkBk\WyuczDlfJBz\XO\|aX7nJJdqdGRidInw[UBDWkGIIHHzd4V{e2WmIHHzJGVTUyCyaH;zdIhwenmuYYTpc44h[XRiMD6zOEB1dyB{MECwNEBvVQ>?	M3HxV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OU[1PFA1Lz5{NUm2OVgxPDxxYU6=
NZM20	NHuxVGNCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MnTsOlghcHK\|		MlXpRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCQWl2yNEBk\WyuczDlfJBz\XO\|aX7nJGIuWmGoIG[2NFBGKG23dHHueEBqe2:uYYTl[EBnem:vIF7le{Bb\WGuYX7kJI1mfGG\|dHH0bYMhdWWuYX7vcYEheGG2aXXueEBqdmO3YnH0[YQh\m:{IE[4JIhzeyCkeTDTVmIh[XO\|YYmsJGlEPTBiPTCwMlAzPCEQvF2u	M{DXTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEC1OVMxLz5{NkCwOVU{ODxxYU6=
NZM07	Ml7XRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MkDTOlghcHK\|		M1PD[GFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTmrNNFch[2WubIOg[ZhxemW\|c3nu[{BDNVKjZjDWOlAxTSCvdYThcpQhcXOxbHH0[YQh\nKxbTDO[ZchYmWjbHHu[EBu\XSjc4TheIlkKG2nbHHuc41iKHCjdHnlcpQhcW6ldXLheIVlKG[xcjC2PEBpenNiYomgV3JDKGG\|c3H5MEBKSzVyIE2gNE4xOzZizszNMi=>	NIX0N\|Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkCwOVU{OCd-Mk[wNFU2OzB:L3G+
A375	Mn\RRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NEnOU4U3QCCqcoO=		NX7EU3h{SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBN\|c2KGOnbHzzJIV5eHKnc4PpcochSi2UYX[gWlYxOEVibYX0ZY51KGmwY4XiZZRm\CCob4KgOlghcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFAvODd7IN88UU4>	NEG1XXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkCwOVU{OCd-Mk[wNFU2OzB:L3G+
COLO205	M4rXTmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MVy2PEBpenN?		MXjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEORTF:yNFUh[2WubIOg[ZhxemW\|c3nu[{BDNVKjZjDWOlAxTSCvdYThcpQhcW6ldXLheIVlKG[xcjC2PEBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gNE4{ODlizszNMi=>	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjByNUWzNEc,OjZyMEW1N\|A9N2F-
SK-MEL-28	MVPBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NX65OXpEPjhiaILz		NH:1bmNCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGPLMW1GVC1{ODDj[YxteyCneIDy[ZN{cW6pIFKtVoFnKFZ4MEDFJI12fGGwdDDpcoN2[mG2ZXSg[o9zKDZ6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSByLkO4NUDPxE1w	M2\KUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEC1OVMxLz5{NkCwOVU{ODxxYU6=
HT-29	NF7WWVhCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NWHFfmpqPjhiaILz		MUPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiWLUK5JINmdGy\|IHX4dJJme3OrbnegRk1T[WZiVk[wNGUhdXW2YX70JIlv[3WkYYTl[EBnd3JiNkigbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuOlAyKM7:TT6=	NYnpboVoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wNFU2OzBpPkK2NFA2PTNyPD;hQi=>
SK-MEL-1	NF\SWWRCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		M3;aR\|Y5KGi{cx?=		NG\lTIVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGPLMW1GVC1zIHPlcIx{KGW6cILld5NqdmdiQj3SZYYhXjZyMFWgcZV1[W62IHnuZ5Vj[XSnZDDmc5IhPjhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDFwNEm5JO69VS5?	MmXhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyMEW1N\|AoRjJ4MEC1OVMxRC:jPh?=
NZM40	NEHaPW1CdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		M2rBUFY5KGi{cx?=		NVTXPJJzSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDOXm01OCClZXzsd{BmgHC{ZYPzbY5oKHerbHSgeJlx\SCELWLh[kBqe2:uYYTl[EBnem:vIF7le{Bb\WGuYX7kJI1mfGG\|dHH0bYMhdWWuYX7vcYEheGG2aXXueEBqdmO3YnH0[YQh\m:{IE[4JIhzeyCkeTDTVmIh[XO\|YYmsJGlEPTBiPTCzMlAyKM7:TT6=	NHv1V3g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkCwOVU{OCd-Mk[wNFU2OzB:L3G+
NZM09	NIn1WHhCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MmXtOlghcHK\|		NYntSJFXSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDOXm0xQSClZXzsd{BmgHC{ZYPzbY5oKHerbHSgeJlx\SCELWLh[kBqe2:uYYTl[EBnem:vIF7le{Bb\WGuYX7kJI1mfGG\|dHH0bYMhdWWuYX7vcYEheGG2aXXueEBqdmO3YnH0[YQh\m:{IE[4JIhzeyCkeTDTVmIh[XO\|YYmsJGlEPTBiPTC4MlM{KM7:TT6=	NY\mdVQxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wNFU2OzBpPkK2NFA2PTNyPD;hQi=>
A375P	MYPBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NVnLN4JRPzJiaILz		MlfDRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCDM{e1VEBk\WyuczDlfJBz\XO\|aX7nJGJTSUZiVk[wNGUhdXW2YX70JIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2ZYKtS4xwKGG\|c3H5MEBKSzVyIE2gNE4{PyEQvF2u	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjd{NEezNEc,OjZ5MkS3N\|A9N2F-
BL21(DE3)	MX7GeY5kfGmxbjDhd5NigQ>?				M1rBXmlvcGmkaYTpc44hd2ZiTj30[ZJucW6jbDDobZMufGGpZ3XkJGJTSUZiVk[wNGUhdXW2YX70JEg1PDhidH:gO\|I{KHKnc3nkeYV{MSBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDFd4Np\XKrY3jpZUBkd2yrIFLMNlEpTEV\|KTDj[YxteyCjc4Pld5Nm\CCjczDwbI9{eGixconsZZRqd25ib3[gZolwfGmweXzheIVlNU2HSzDifUBCdHCqYWPjdoVmdiCjc4PhfUwhUUN3MDC9JFAvODNzIN88UU4>	NGL3eXY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nki1NlYzOyd-Mk[4OVI3OjN:L3G+
A375	M37FUGZ2dmO2aX;uJIF{e2G7		NY\hUZd6OSCqch?=		NEXRWmVKdmirYnn0bY9vKG:oIFKtVoFnKFZ4MEDFJI12fGGwdDDpckBpfW2jbjDBN\|c2KGOnbHzzJIF{e2W\|c3XkJIF{KEWUSzDwbI9{eGixconsZZRqd25icILlbY5kfWKjdHXkJIZweiBzIHjyJIJ6KFenc4Tldo4h[myxdDDt[ZRpd2RuIFnDOVAhRSByLkCxO{DPxE1w	M{P1b\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MEi1OlczLz5{N{C4OVY4OjxxYU6=
MIAPaCa2	MVLGeY5kfGmxbjDhd5NigQ>?		MkSwNUBpeg>?		MnPkTY5pcWKrdHnvckBw\iC5aXzkJJR6eGViQj3SZYYhcW5iaIXtZY4hVUmDUHHDZVIh[2WubIOgZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKGmwIFXST{BxcG:\|cHjvdplt[XSrb36gdJJmcW6ldXLheIVlKG[xcjCxJIhzKGK7IGfld5Rmem5iYnzveEBu\XSqb3SsJGVEPTBiPTCyMlI6KM7:TT6=	NVvhOXBnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkewPFU3PzJpPkK3NFg2Pjd{PD;hQi=>
COLO205	M3u0ZWN6fG:2b4jpZ4l1gSCjc4PhfS=>		NF6y[Zc4OiCqcoO=		MYrDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDDU2xQOjB3IHPlcIx{KGijcnLvdolv\yCELWLh[kBXPjByRTDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuNFQ1KM7:TT6=	NXG0eFhqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkexOVU5QTlpPkK3NVU2QDl7PD;hQi=>
HT-29	MWjDfZRwfG:6aXPpeJkh[XO\|YYm=		MUO3NkBpenN?		MVvDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIWE0zQSClZXzsd{Bp[XKkb4LpcochSi2UYX[gWlYxOEVibYX0ZY51KGG\|c3Xzd4VlKGG\|IHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSByLkG1OkDPxE1w	M{e2RVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUW1PFk6Lz5{N{G1OVg6QTxxYU6=
HCT116	MXvDfZRwfG:6aXPpeJkh[XO\|YYm=		MoTxO\|IhcHK\|		NEjYV25EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJS1RzMU[gZ4VtdHNiaHHyZo9zcW6pIIfpcIQhfHmyZTDCMXJi\iCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMUSuOVgh\|ryPLh?=	NETWbIk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{G1OVg6QSd-MkexOVU5QTl:L3G+
WM266.4	NE\YWmZCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NWGyO\|FXOjRiaILz		M1TYTWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iV12yOlYvPCClZXzsd{Bie3Onc4Pl[EBieyClZXzsJJZq[WKrbHn0fUBi\nSncjCyOEBpenNiYomgUXRVKGG\|c3H5MEBIUTVyIE2gNE4zOSEQvF2u	M{jxUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MkO4PFQyLz5{N{KzPFg1OTxxYU6=
WM266.4	NFHiXmpCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MmjKNlQhcHK\|		NI\QbGxCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGfNNlY3NjRiY3XscJMhcGG{Yn;ybY5oKEKUQV[gWlYxOEVibYX0ZY51KGG\|c3Xzd4VlKGG\|IHPlcIwh\3Kxd4ToJIlvcGmkaYTpc44h[W[2ZYKgNlQhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFAvODdizszNMi=>	NILzem89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{[zOFE6PSd-Mke2N\|QyQTV:L3G+
A375	NEf4NI1CdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MYiyOEBpenN?		Ml3LRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCDM{e1JINmdGy\|IHHzd4V{e2WmIHHzJINmdGxiZ4Lve5RpKGmwaHnibZRqd25iYX\0[ZIhOjRiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDBwMkGg{txONg>?	MlWzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd4M{SxPVUoRjJ5NkO0NVk2RC:jPh?=
WM1361	NFPaWIlCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NVu0cpR{OjRiaILz		Mof3RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCZTUGzOlEh[2WubIOgZZN{\XO\|ZXSgZZMh[2WubDDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB{NDDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMT64OkDPxE1w	MoLXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd4M{SxPVUoRjJ5NkO0NVk2RC:jPh?=
SK-MEL-28	MUTBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		Mn;jOFghcHK\|		M3H6[2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU1utUWVNNTJ6IHPlcIx{KGijcnLvdolv\yCEUlHGJHY3ODCHIH31eIFvfCCjc4Pld5Nm\CCjczDjc45k\W62cnH0bY9vKHKncYXpdoVlKG[xcjD0c5RidCCpcn;3eIghcW6qaXLpeIlwdiCvZXHzeZJm\CCjZoTldkA1QCCqcoOgdoV{[Xq3cnnuJIF{e2G7LDDUS2khRSB{IN88UU4>	NVPnSFk6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke3O\|QyOzdpPkK3O\|c1OTN5PD;hQi=>
SK-MEL-28	NYPHfWVjT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		Mon6NUBpeg>?		M{WwWWdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJHNMNU2HTD2yPEBk\WyuczDoZZJjd3KrbnegRnJCTiCYNkCwSUBufXSjboSgdJJmcW6ldXLheIVlKG[xcjCxJIhzKG[xbHzve4VlKGK7IHnydoFlcWG2aX;uJI9nKDFwMUOgb3cwdTJiVW[tcIlocHRiZn;yJFUhdWmwczDt[YF{fXKnZDDh[pRmeiB2ODDodpMhemW\|YYr1dolvKGG\|c3H5	NXvPZ2d3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke3O\|QyOzdpPkK3O\|c1OTN5PD;hQi=>
A375	NFnOPJNCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NVTYdJdkPzJiaILz		NHTqOZZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBpfW2jbjDBN\|c2KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDj[YxtKHSrdHXyMYdtdyCudX3pcoV{[2WwY3WgZZN{[XluIFnDOVAhRSByLkeg{txONg>?	NYDpOIpbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyOFI2PTNpPkK4NlQzPTV\|PD;hQi=>
COLO205	NXvRSlFvSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MkCwO\|IhcHK\|		MUPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDoeY1idiCFT1zPNlA2KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDj[YxtKHSrdHXyMYdtdyCudX3pcoV{[2WwY3WgZZN{[XluIFnDOVAhRSB3LkG2JO69VS5?	MnzLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{NEK1OVMoRjJ6MkSyOVU{RC:jPh?=
HepG2	MnrxRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		M135V\|czKGi{cx?=		NVH5fYVFSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkhcHWvYX6gTIVxTzJiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JINmdGxidHn0[ZIu\2yxIHz1cYlv\XOlZX7j[UBie3OjeTygTWM2OCB;IEWuOFgh\|ryPLh?=	NXX4enN[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyOFI2PTNpPkK4NlQzPTV\|PD;hQi=>
SK-MEL-2	M4mxTGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NHj0e4g4OiCqcoO=		MoXtRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgbJVu[W5iU1utUWVNNTJiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JINmdGxidHn0[ZIu\2yxIHz1cYlv\XOlZX7j[UBie3OjeTygTWM2OCB;IEWuOlQh\|ryPLh?=	Mnz4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{NEK1OVMoRjJ6MkSyOVU{RC:jPh?=
K562	NIrIZlRHfW6ldHnvckBie3OjeR?=		M4L2VFEhcHJ?		MlvsV5Ri[mmuaYrheIlwdiCxZjDCVmFHKGmwIHj1cYFvKEt3NkKgZ4VtdHNiYX\0[ZIhOSCqcjDifUB1cGW{bXHsJJNpcW[2IHHzd4F6NCCHQ{WwJF0hOC55OUSzN{DPxE1w	NInzN409[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NFI3OSd-MkiyPFAzPjF:L3G+
K562	M4m5bWZ2dmO2aX;uJIF{e2G7		MlHqNUBpeg>?		MX;TeIFjcWyrenH0bY9vKG:oIF\FR2ghcW5iaIXtZY4hUzV4MjDj[YxteyCjZoTldkAyKGi{IHL5JJRp\XKvYXygd4hq\nRiYYPzZZktKEWFNUCgQUA2NjBzMUi3JO69VS5?	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MEK2NUc,Ojh{OECyOlE9N2F-
A375M	MVHBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MWC3NkBpenN?		NYPsdXRLSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBN\|c2VSClZXzsd{Bp[XKkb4LpcochSlKDRjDWOlAxTSCvdYThcpQh[W[2ZYKgO\|IhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFAvPSEQvF2u	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR3OEGzOEc,Ojh2NUixN\|Q9N2F-
1205 Lu	MXzBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		Mn\nO\|IhcHK\|		MUfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKDF{MEWgUJUh[2WubIOgbIFz[m:{aX7nJGJTSUZiVk[wNGUhdXW2YX70JIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCyJO69VS5?	MoDJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2NUixN\|QoRjJ6NEW4NVM1RC:jPh?=
A375M	MYPBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MV:0PEBpenN?		NHfyOJNCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFGzO\|VOKGOnbHzzJIhiemKxcnnu[{BDWkGIIG[2NFBGKG23dHHueEBi\nSncjC0PEBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gNk4xPSEQvF2u	NEXiPGc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OES1PFE{PCd-Mki0OVgyOzR:L3G+
UACC-903	M1ywWGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MYC3NkBpenN?		MmLORY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCXQVPDMVkxOyClZXzsd{Bp[XKkb4LpcochSlKDRjDWOlAxTSCvdYThcpQh[W[2ZYKgO\|IhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFIvPyEQvF2u	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR3OEGzOEc,Ojh2NUixN\|Q9N2F-
1205 Lu	MWPBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NVT0bJpNPDhiaILz		NGHTPYVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIEGyNFUhVHViY3XscJMhcGG{Yn;ybY5oKEKUQV[gWlYxOEVibYX0ZY51KGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUA4NjZizszNMi=>	M3LIb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEW4NVM1Lz5{OES1PFE{PDxxYU6=
UACC-903	M{\DZ2FvfGmycn;sbYZmemG2aY\lJIF{e2G7		MV[0PEBpenN?		M4XCb2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iVVHDR{06ODNiY3XscJMhcGG{Yn;ybY5oKEKUQV[gWlYxOEVibYX0ZY51KGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUAyOi5\|IN88UU4>	M2LuTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEW4NVM1Lz5{OES1PFE{PDxxYU6=
CHL-1	M3HM[GFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NXnrSo91PzJiaILz		Mn:4RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCFSFytNUBk\WyuczDoZZJjd3Krbnege4lt\CC2eYDlJGJTSUZiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDF{Lkeg{txONg>?	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR3OEGzOEc,Ojh2NUixN\|Q9N2F-
CHL-1	MmnURY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		M4nvfVQ5KGi{cx?=		M{CwZWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQ1jMMVEh[2WubIOgbIFz[m:{aX7nJJdqdGRidInw[UBDWkGIIHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSB{MDFOwG0v	NGHufmE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OES1PFE{PCd-Mki0OVgyOzR:L3G+
HCT116	NXO0cFFITnWwY4Tpc44h[XO\|YYm=				NGXrTXNUfGmvdXzheIlwdiCxZjDCVmFHNUOUQV[g[Ilu\XKrenH0bY9vKGmwIHj1cYFvKEiFVEGxOkBk\WyuczDifUBtfWOrZnXyZZNmKGOxbYDs[Y1mdnSjdHnvckBie3OjeTygSWM2OCB;IECuOlAyKM7:TT6=	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDV3N{S1PEc,Ojh3NUe0OVg9N2F-
Calu6	NXvFTXl1TnWwY4Tpc44h[XO\|YYm=	NXu2R4kzOyC3TR?=	MnvMNkBpenN?		MXvBZ5RqfmG2aX;uJI9nKEOUQV[gbY4hcHWvYX6gR4FtfTZiY3XscJMh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gUWVMKHCqb4PwbI9zgWyjdHnvckBifCB\|IIXNJIFnfGW{IEKgbJJ{KGK7IF\SSXQh[XO\|YYm=	NX7mbmhSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki1OVc1PThpPkK4OVU4PDV6PD;hQi=>
Sf9	M2Ho[2Z2dmO2aX;uJIF{e2G7		M3HYelEhcHJ?		M{HL[mlvcGmkaYTpc44hd2ZiaIXtZY4hYkGNIDi1JJRwKDNyOTDy[ZNq\HWnczmg[ZhxemW\|c3XkJIlvKGKjY4Xsc5ZqenW\|IHnu[oVkfGWmIGPmPUBqdnOnY4SgZ4VtdHNidYPpcochYkGNdHnk[UBieyC\|dXLzeJJifGViYX\0[ZIhOSCqcjDifUBu[XO\|IIPw[YN1em:vZYTyfUwhUUN3MDC9JFAvODJ\|IN88UU4>	MmTYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh3OE[yNVEoRjJ6NUi2NlEyRC:jPh?=
Sf9	NUfMeJpxTnWwY4Tpc44h[XO\|YYm=		NHjjZ3Y{OCCvaX7z		M3\pdWlvcGmkaYTpc44hd2ZiTj30[ZJucW6jbDDHV3QufGGpZ3XkJJJm[2:vYnnuZY51KGi3bXHuJIZ2dGxvbHXu[5RpKFqDSzDlfJBz\XO\|ZXSgbY4h[mGldXzveolzfXNiaX7m[YN1\WRiU3[5JIlve2WldDDj[YxteyC3c3nu[{BOSlBiYYOgd5Vje3S{YYTlJIFnfGW{IEOwJI1qdnNiYomgRWRRNUeubzDhd5NigSxiSVO1NEA:KDBwMEOxOEDPxE1w	NGC1WYg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEW4OlIyOSd-Mki1PFYzOTF:L3G+
UACC-903	NH:wOYhEgXSxdH;4bYNqfHliYYPzZZk>	MX[yOUB2VQ>?	NGOyT401QCCqcoO=		M3TINmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHVCS0NvOUCzJINmdGy\|IHHzd4V{e2WmIHHzJINmdGxidnnhZoltcXS7IHH0JFI2KHWPIHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XlicnXsZZRqfmVidH:gZ49vfHKxbDygTWM2OCB;IEOuOkDPxE1w	NX25SGZuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmxN\|MxOzVpPkK5NVM{ODN3PD;hQi=>
CHL-1	NVfEXXI5SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NHnaTXE4OiCqcoO=		NH;VOZNCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFPIUE0yKGOnbHzzJIhiemKxcnnu[{B4cWymIIT5dIUhSlKDRjDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMUOuO{DPxE1w	MlvrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjlzM{OwN\|UoRjJ7MUOzNFM2RC:jPh?=
A375	M13WVWZ2dmO2aX;uJIF{e2G7		NYK0dGZnQTZiaILz		NXXyeogyUW6qaXLpeIlwdiCxZjDCVmFHKFZ4MEDFJI12fGGwdDDpckBpfW2jbjDBN\|c2KGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKHC{b3zp[oVz[XSrb36gbY5kfWKjdHXkJIZweiB7NjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMD6xNlch\|ryPLh?=	NH7uZ2o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSwO\|k4Pyd-Mkm0NFc6Pzd:L3G+
A375	M4PkdWZ2dmO2aX;uJIF{e2G7				MWfJcohq[mm2aX;uJI9nKEKUQV[gWlYxOEVibYX0ZY51KGmwIHj1cYFvKEF\|N{WgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKEWUSzDwbI9{eGixconsZZRqd25iYomgRYxxcGGVY4Ll[Y4h[XO\|YYmsJGlEPTBiPTCwMlA{OiEQvF2u	NH7MPII9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUS2NVgzPyd-Mkm0OlE5Ojd:L3G+
SK-MEL-32	NHTkcpZEgXSxdH;4bYNqfHliYYPzZZk>				NVLobFVlS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW0tvTVXMMVMzKGOnbHzzMEBKSzVyIE2gNE4{OSEQvF2u	NUXWd5VSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0OlE5OjdpPkK5OFYyQDJ5PD;hQi=>
WM266.4	NIPwOVhCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MXi0PEBpenN?		NFPiRmJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGfNNlY3NjRiY3XscJMh[W[2ZYKgOFghcHK\|IHL5JG1VXCCjc4PhfUwhT0l3MDC9JFAvOjFizszNMi=>	NVjPVYY4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm5OFA1PjNpPkK5PVQxPDZ\|PD;hQi=>
A375	M{f0TmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NX[0cZZ{PDhiaILz		NFzXUZhCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFGzO\|Uh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygS2k2OCB;IECuPVUh\|ryPLh?=	MkPnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl7NEC0OlMoRjJ7OUSwOFY{RC:jPh?=
HT-29	NHv2NHFCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		Mn[2OFghcHK\|		NUfVfFFtSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIWE0zQSClZXzsd{Bi\nSncjC0PEBpenNiYomgUXRVKGG\|c3H5MEBIUTVyIE2gNU45QCEQvF2u	NHnROW09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUm0NFQ3Oyd-Mkm5OFA1PjN:L3G+
WM1361	NUXvZXpZSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M1\r[VQ5KGi{cx?=		M1yxOWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iV12xN\|YyKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO\|YYmsJGdKPTBiPTCyNE45KM7:TT6=	MkLkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl7NEC0OlMoRjJ7OUSwOFY{RC:jPh?=
HCT116	NEDSOXpCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NH61NYo1QCCqcoO=		NYrxZ4RPSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[W[2ZYKgOFghcHK\|IHL5JG1VXCCjc4PhfUwhT0l3MDC9JFI2NjJizszNMi=>	MkHiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl7NEC0OlMoRjJ7OUSwOFY{RC:jPh?=
A673	MX\xTHRUKGG\|c3H5				MYLxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSTZ5MzDj[Yxtew>?	NFLNNoM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
DAOY	MlfLdWhVWyCjc4PhfS=>				NGq3VXNyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiRFHPXUBk\Wyucx?=	M3n1bFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
RD	MmDpdWhVWyCjc4PhfS=>				MW\xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWkRiY3XscJM>	MkPuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SK-N-SH	MXzxTHRUKGG\|c3H5				MonGdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tV2gh[2WubIO=	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
MG 63 (6-TG R)	NWPMRnZ5eUiWUzDhd5NigQ>?				MYPxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVUdiNkOgLFYuXEdiUjmgZ4VtdHN?	M4j5PFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB1643	M1X4ZZFJXFNiYYPzZZk>				M2LReZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCQQkG2OFMh[2WubIO=	MkT0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
OHS-50	MXPxTHRUKGG\|c3H5				NF6xUYtyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiT1jTMVUxKGOnbHzz	MnXaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
A673	MUHxTHRUKGG\|c3H5				NFj6W5RyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBCPjd\|IHPlcIx{MQ>?	MnHTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
U-2 OS	MoDTdWhVWyCjc4PhfS=>				NXqzcI5ZeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhXS1{IF;TJINmdGy\|	M3vETFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh41	M3nGepFJXFNiYYPzZZk>				NWWwV49EeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhWmh2MTDj[Yxtew>?	MlLXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SJ-GBM2	MU\xTHRUKGG\|c3H5				M3rx[JFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSj3HRm0zKGOnbHzz	NGXOZnY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SK-N-MC	NW\jS4JseUiWUzDhd5NigQ>?				MVfxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0tvTj3NR{Bk\Wyucx?=	Ml;pQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
LAN-5	MmTPdWhVWyCjc4PhfS=>				MUDxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVEGQLUWgZ4VtdHN?	MlLXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SK-N-MC	M3i1ZpFJXFNiYYPzZZk>				Mo\idWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgV2suVi2PQzDj[Yxtew>?	NVzwfG54RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
TC32	NHPlXIhyUFSVIHHzd4F6				MX\xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDUR\|MzKGOnbHzz	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-ERK / p-CRAF; PubMed: 22448344 Cancer Discov BRAF mutant cell lines from (A) were treated with 3µM vemurafenib for the indicated times, and lysates were probed with the indicated antibodies. p-MEK(S217/221) / pAKT(T308) / p-AKT(S473) / p-P70 S6K(T389) / p-S6(Ser235-236) / P-4EB-P1; PubMed: 22194965 PLoS One Western blot analysis of phosphorylated and the total amount of key proteins in the MAPK and PI3K/AKT pathways after 24 hours of exposure to the solvent (DMSO), or various concentrations of the BRAF inhibitor vemurafenib. The vemurafenib-sensitive M238 and M229 cell lines and the vemurafenib in vitro acquired resistant sublines M238-AR2 and M229-AR9 were cultured at different concentrations of vemurafenib. p70 and p-p70 S6K in this figure are referred to S6K1 and phosphorylated form of S6K1, respectively. Bax / Bcl2 / Bcl-xl / BIM / Mcl1; PubMed: 28382170 Theranostics Change of Bcl-2 family proteins following Vemurafenib treatment for 24 h.	22448344 22194965 28382170
Growth inhibition assay	Cell viability; PubMed: 29179510 Oncotarget At different time point of the experiment (expressed in days), sensitivity to vemurafenib was evaluated in the different A375 cell lines. Cells were treated with 10-fold dilution series (1 nM to 10 uM) of Vemurafenib and cell viability was assessed after 72 h by Crystal violet staining. Cell viability results are expressed in fold vs. the untreated cells.	29179510
Immunofluorescence	uPAR / α5-β1; PubMed: 30611716 EBioMedicine Representative images of confocal microscopy of companion M6R treated cultures stained with specific anti-uPAR (red), α5β1 (green) and DAPI (blue). Experiments have been performed three times in triplicate with analogous results. The co-localization score is quantified by image J andreported within each picture as Manders' coefficient (MC). The shown pictures are representative of 20 different pictures for each experimental condition. Scale bar = 20 μm. p-Akt(Thr308); PubMed: 27293997 Am J Cancer Res Vemurafenib reduced phosphorylated Akt in HUVEC. Cells were treated with vemurafenib for 4 h and processed for immunofluorescence staining with antibodies against p-AktThr308. Cell nuclei were stained with DAPI. Scale bar represents 50 μm.	30611716 27293997

体内研究

PLX4032按6 mg/kg-20 mg/kg 剂量作用于B-RAF^V600E-突变鼠移植瘤模型，抑制肿瘤生长。^[1] PLX4032按12.5 mg/kg-100 mg/kg剂量作用于携带LOX, Colo829, 和A375移植瘤小鼠，抑制肿瘤生长，延长小鼠寿命。^[2]

激酶实验： ^[1]	- 合并 RAF激酶活性测定: 通过测量生物素化的BAD蛋白磷酸化而测定野生型RAF和突变型的激酶活性。在20 mM Hepes (pH 7.0), 10 mM MgCl₂, 1 mM DTT, 0.01% (v/v) Tween-20, 50 nM 生物素-BAD 蛋白，和 1 mM ATP 的混合物中室温下进行反应。加入5 μL 含20 mM Hepes (pH 7.0), 200 mM NaCl, 80 mM EDTA, 0.3% (w/v) 牛血清蛋白 (BSA)的溶液，5分钟后，反应终止。终止溶液也包含p-BAD (Ser112) 抗体,链霉亲和素包被的供体小珠，蛋白A 受体小珠。抗体和小珠在终止溶液中黑暗环境下室温预温育30分钟。最终抗体被稀释2000倍，每个小珠的终浓度为10 μg/mL。重复做三次单独纯化蛋白实验，去不同两批的平均值作为突变活性。
细胞实验： ^[2]	- 合并 Cell lines: MALME-3M, Colo829, Colo38, A375, SK-MEL28, 和 A2058 细胞 Concentrations: 0–10 μM , 溶于 DMSO Incubation Time: 5 天 Method: 通过MTT 实验测评细胞增殖。细胞按每孔1000到5000个接种在96孔板上，体积为180 μL。PLX4032按最终实验浓度的10倍储备在含1% DMSO的培养基中。细胞接种24小时后, 加入20 μL适当稀释的PLX4032。接种6天后，进行增殖实验。计算抑制百分数，根据抑制百分数与浓度的对数的回归分析测定IC50值。 (Only for Reference)
动物实验： ^[2]	- 合并 Animal Models: 携带LOX, Colo829, 和A375移植瘤细胞的无胸腺裸鼠 Dosages: 12.5 mg/kg–100 mg/kg Administration: 口服饲喂，每天两次 (Only for Reference)

参考文献

- 合并

溶解度 (25°C)

体外	DMSO	97 mg/mL (197.99 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 4% DMSO+30% PEG 300+5% Tween 80+61% ddH2O	1.25mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Vemurafenib (PLX4032) SDF

分子量	489.92
化学式	C₂₃H₁₈ClF₂N₃O₃S
CAS号	918504-65-1
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	RG7204, RO5185426

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2021-05-17)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03013491	Active not recruiting	Drug: CX-072\|Drug: ipilimumab\|Drug: vemurafenib	Solid Tumor\|Lymphoma	CytomX Therapeutics	January 2017	Phase 1\|Phase 2
NCT02441465	Completed	Drug: Vemurafenib\|Drug: 14C-Labeled Vemurafenib	Malignant Melanoma Cancer	Hoffmann-La Roche	August 13 2015	Phase 1
NCT02427893	Withdrawn	Drug: Cobimetinib\|Drug: Vemurafenib	Melanoma	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|Genentech Inc.	August 2015	Phase 3
NCT02036086	Active not recruiting	Drug: Vemurafenib\|Drug: Cobimetinib	Melanoma	Sunnybrook Health Sciences Centre	August 2015	Phase 2
NCT02456701	Completed	Biological: KTN3379\|Drug: vemurafenib	Thyroid Cancer	Celldex Therapeutics\|Memorial Sloan Kettering Cancer Center	June 2015	Phase 1
NCT02304809	Active not recruiting	Drug: Vemurafenib	Solid Tumors\|Hematologic Cancers\|Metastatic Cancers	UNICANCER\|National Cancer Institute France\|Fondation ARC\|Hoffmann-La Roche	October 13 2014	Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
How about the half-life of Vemurafenib(S1267)?
回答：
It was reported that the half-life of the compound is 57 hours.
问题 2：
The vemurafenib power, when prepared in 4% DMSO/30% PEG 300/5% Tween 80/ddH2O solutions, form a pellet down the tube?
回答：
When prepare this kind of vehicle, please dissolve the drug in DMSO clearly first. If it dissolves not readily, please sonicate and warm in the water bath at about 45 degree. Then add PEG and Tween. After they mixed homogeneously, then dilute with water.

Raf Signaling Pathway Map

Raf Inhibitors with Unique Features

选择性强的Raf抑制剂

SB590885 : B-Raf-selective, K_i=0.16 nM.
选择性强的Raf抑制剂

ZM 336372 : C-Raf-selective, IC50=70 nM.
FDA批准的Raf抑制剂

Sorafenib Tosylate : Approved by FDA for advanced renal cancer.
最新的Raf抑制剂

TAK-632 ^New : Potent pan-Raf inhibitor with IC50 of 8.3 nM and 1.4 nM for B-Raf(wt) and C-Raf, respectively, showing less or no inhibition against other tested kinases.

研究领域

产品类型

定制您的化合物库

Vemurafenib (PLX4032)

客户使用Selleck生产的Vemurafenib (PLX4032)发表文献492篇：

产品安全说明书

Raf抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Vemurafenib (PLX4032) SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2021-05-17)

技术支持

常见问题及建议解决方法

Raf Signaling Pathway Map

Raf Inhibitors with Unique Features

相关Raf产品